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ABSTRACT 
 
Cutis laxa (CL) is a genetic disorder of connective tissue. CL has known effects on 
multiple body systems, but its relationship to immune function has not been characterized. 
Recently, the laboratory of Jordan Orange, MD, PhD identified a patient with immune deficiency 
disease who also had a mutation in a known CL-causing gene, ATP6V0A2. This observation 
prompted us to look for evidence of immune dysfunction among individuals with ATP6V0A2- 
related CL. We administered an infection history survey to study participants with ATP6V0A2- 
related CL, their unaffected relatives, and individuals with ELN-related CL. We calculated a 
novel age weighted infection score for each participant and compared the three groups. We  
found that individuals with ATP6V0A2-related CL had significantly higher infection scores than 
unaffected family members (p=0.0004) or individuals with ELN-related cutis laxa (p=0.0016). 
These data suggest that ATP6V0A2 mutations have a deleterious effect on immune function. Our 
findings have public health significance because they further characterize the natural history of 
ATP6V0A2-related CL and thus enhance our ability to assess this condition in the population. 
The infection history questionnaire has the potential to be used in guiding genetic testing and in 
guiding medical management, support the public health function of policy development. In 
addition, research in CL is relevant to aging and to conditions that affect larger populations, such 
as asthma, chronic obstructive pulmonary disease, and heart disease. 
Zsolt Urban, PhD 
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1.0  INTRODUCTION 
Cutis laxa (CL) is a family of connective tissue disorders (Berk, Bentley, Bayliss, Lind, 
& Urban, 2012) affecting approximately 300 families worldwide.  The most prevalent feature in 
CL is loose, wrinkled skin, giving an aged appearance to individuals affected by this condition.  
There is variable systemic involvement, although pulmonary and cardiovascular complications 
are common.  The nervous system, musculoskeletal system, and genitourinary system can also be 
affected.  The constellation of symptoms seen in a particular individual is largely dependent on 
the underlying genetic cause of the condition.  CL is usually diagnosed by a combination of 
clinical exam, abnormal structure and reduced number of elastic fibers by skin biopsy, and 
genetic testing (Berk et al., 2012). 
Approximately one third of CL cases in our study group have a known genetic cause, and 
the others are of unknown etiology.   Mutations in a dozen genes have been associated with CL 
and the resulting clinical phenotypes have been characterized.  These monogenic forms of CL 
can be present from birth or, less commonly, can manifest in childhood or early adulthood.  An 
acquired form of cutis laxa is also known (Lewis, Bercovitch, Dill, & Robinson-Bostom, 2004) , 
for which no genetic cause or susceptibility factor has been identified with the exception of one 
case (Hu, Reymond, Pinel, Zabot, & Urban, 2006). 
While CL is known to be a multi-system disorder, investigators have not examined 
potential effects of CL on the immune system.  We began to study immune function in 
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ATP6V0A2-related CL in collaboration with the laboratory of Jordan Orange, MD, PhD, after a 
case report identified an individual with CL and Epstein-Barr-associated smooth muscle tumors.  
These rare tumors are seen in conditions associated with immune deficiency, such as AIDS 
(Deyrup et al., 2006).  The individual’s presentation included CL, aortic root dilation, fetal 
alcohol syndrome, intellectual disability and developmental delay.  Immunological investigations 
determined that the patient had a natural killer (NK) cell deficiency and that this abnormality was 
the mechanism for the patient’s immune deficiency (Shaw et al., 2012).  Exome sequencing later 
revealed an ATP6V0A2 mutation (Orange, personal communication).  
We hypothesized that other individuals with ATP6V0A2-related CL would have reduced 
immune function.  To test this idea, we collected and analyzed data on infection history from 
individuals enrolled in our CL study, which characterizes genotype-phenotype relationships in 
individuals with cutis laxa and their unaffected first-degree relatives.  A subset of individuals 
enrolled in the CL study traveled to Pittsburgh to participate in a research clinic, at which we 
collected blood and biopsy samples.  Participants also underwent echocardiograms, DXA bone 
density scans, pulmonary function testing, chest CT scans, facial imaging, and skin and vascular 
elasticity measurements.  They also had a genetic evaluation and a meeting with Zsolt Urban, 
PhD, the principal investigator of the study.  Participants also completed a battery of 
questionnaires, among them an infection history questionnaire.  We calculated a novel infection 
score from the questionnaire data, and tested the hypothesis that individuals with ATP6V0A2-
related CL would have a higher infection score than unaffected relatives or individuals with other 
types of CL.  Our findings support this hypothesis, and add to our understanding of the clinical 
phenotype in ATP6V0A2-related CL. 
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2.0  LITERATURE REVIEW 
2.1 ELASTIC FIBER FORMATION 
Elastic fiber abnormalities are present in all types of CL, and it is necessary to understand 
elastic fiber composition in order to understand the molecular basis of CL.  Elastic fibers are part 
of the extracellular matrix (ECM), a complex and dynamic biological scaffolding that not only 
provides support for cells, but also regulates many biological processes through storage of 
growth factors and cytokines, interactions with cell surface receptors, alterations in cytoskeletal 
structures in response to environmental changes, and initiation of signaling cascades (Baldwin, 
Simpson, Steer, Cain, & Kielty, 2013).  Other components of the ECM are proteoglycans,  
elastin, collagens, and a large number of glycoproteins including fibronectin and laminin.  
Components of the ECM are made inside cells and secreted into the extracellular space, where 
they are assembled into fibers, sheets, or three-dimensional networks.  Modifications to these 
components can occur at both pre-secretion and post-secretion stages (Carson, 2004). 
An elastic fiber is made up of two components, the amorphous core and the microfibrils.  
The amorphous core, composed primarily of elastin, accounts for the bulk of the elastic fiber.  
Elastin is a polymeric protein that is formed by crosslinking of tropoelastin monomers.  The 
crosslinking is accomplished through the action of lysyl oxidase, which is a copper-dependent 
enzyme.  The second component of the elastic fiber, the microfibril, contains fibrillin and 
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glycoproteins.  Microfibrils provide the structure upon which elastin is deposited.  Other 
components of the ECM, such as fibulins, deposit elastin at the point where the microfibrils meet 
the amorphous core (Alberts et al., 2002b).     
2.2 REVIEW OF GENETIC FORMS OF CUTIS LAXA 
2.2.1 ELN-related cutis laxa 
Elastin (ELN)-related CL is also known as autosomal dominant CL (ADCL).  Until 
recently, ELN-related CL was the only known form of CL inherited in an autosomal dominant 
manner.  However, autosomal dominant forms of ALDH18A1-related CL have also been reported 
recently ((Bhola et al., 2017; Fischer-Zirnsak et al., 2015; Nozaki et al., 2016).  ELN-related CL 
is the mildest form of CL, and most affected individuals live a normal lifespan.  Symptoms of 
ELN-related CL can be limited to loose skin, but systemic manifestations are possible.  These 
include emphysema, bronchiectasis, aortic dilation and aortic aneurysm (Szabo et al., 2006; 
Urban, Gao, Pope, & Davis, 2005). The musculoskeletal, genitourinary and GI systems can be 
affected, with resulting hernias, genital prolapse, and diverticula.  Individuals with ELN-related 
CL have characteristic facial features, which include large ears and a hooked nose with a long 
philtrum (Bert Callewaert et al., 2011; Hadj-Rabia et al., 2013). 
The ELN gene codes for tropoelastin, a precursor monomer that is crosslinked to form the 
elastin polymer.  ELN-related CL is an autosomal dominant condition, but roughly 30% of cases 
are not inherited but are instead caused by a de novo mutation (Berk et al., 2012).  The majority 
of mutations causing ELN-related CL are frameshift mutations near the C-terminus of the gene 
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that result in an elongated version of tropoelastin.  The abnormal tropoelastin monomers exhibit 
reduced binding to fibrillin scaffolding but are prone to self-aggregation.  This prevents the 
formation of normal elastin polymers and results in decreased elasticity in skin and other tissues 
(Bert Callewaert et al., 2011; Zhang et al., 1999).  ELN mutations are also associated with 
increased TGF-beta signaling, upregulation of unfolded protein response, and increased 
apoptosis, which are hypothesized to contribute to emphysema in ELN-related CL (Hu et al., 
2010; Urban, Gao, Michael Pope, & Davis, 2005). 
2.2.2 FBLN5-related cutis laxa 
Fibulin-5 (FBLN5)-related CL is also known as autosomal recessive CL type 1A 
(ARCL1A).  It is characterized by congenital onset and severe systemic involvement. Pulmonary 
artery stenosis and severe developmental emphysema make this condition life-limiting (Van 
Maldergem & Loeys, 2014).  Inguinal hernias, genitourinary diverticula, and supravalvular aortic 
stenosis have also been reported (Loeys et al., 2002). FBLN5 contributes to the formation of 
connective tissue by depositing tropoelastin onto fibrillin-1 microfibril scaffolding (Papke & 
Yanagisawa, 2014).  It binds fibrillin-1 (FBN1) (Freeman et al., 2005) and lysyl oxidase-like-1 
(LOXL1), an enzyme involved in the crosslinking of elastic fibers (Liu et al., 2004).  It also 
binds latent transforming growth factor beta binding protein 2 (LTBP2) (Hirani, Hanssen, & 
Gibson, 2007), and latent transforming growth factor beta binding protein 4 (LTBP4) (Noda et 
al., 2013), two other ECM proteins involved in the assembly of elastic fibers. 
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2.2.3 FBLN4-related cutis laxa 
Fibulin 4 (FBLN4)-related CL is also known as epidermal growth factor domain 
containing fibulin-like extracellular matrix protein 2 (EFEMP2)-related CL or autosomal 
recessive CL type 1B (ARCL1B).  Like FBLN5-related CL, it is also characterized by congenital 
onset and systemic involvement.  Developmental pulmonary emphysema, arterial tortuosity, 
aneurysms, and diaphragmatic hernia are common features.  Physical features such as 
retrognathia, arachnodactyly, and bone fragility have also been described (Loeys, De Paepe, & 
Urban, 2015).  The severity of this condition is variable and ranges from lethal cardiovascular 
and pulmonary features to benign arterial tortuosity without skin or lung manifestations (Renard 
et al., 2010). From a molecular standpoint, FBLN4 interacts with fibrillin-1 microfibrils.  FBLN4 
also participates in elastic fiber formation by binding to lysyl oxidase, which mediates the 
crosslinking of elastic fiber components (Papke & Yanagisawa, 2014).  Loss of function 
mutations in FBLN4 lead to impaired secretion of elastic fiber components, dysfunctional 
FBLN4 protein associations and abnormal elastic fiber production (Sasaki et al., 2016).  
2.2.4 LTBP4-related cutis laxa 
LTBP4-related CL is also known as autosomal recessive cutis laxa type 1C (ARCL1C) or 
Urban-Rifkin-Davis Syndrome (URDS).  It is a congenital condition characterized by a severe 
clinical phenotype, with a childhood mortality rate of 76% (Callewaert & Urban, 2016).   
Pulmonary emphysema is the primary cause of death.  In addition to respiratory symptoms, 
pulmonary artery stenosis, inguinal hernias, diverticula, diaphragmatic hernia, congenital heart 
disease, and physical features such as sagging cheeks and sparse hair have been described 
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(Urban et al., 2009).  LTBP4, or latent transforming growth factor beta binding protein 4, 
participates in elastogenesis by interacting with both the fibrillin-1 scaffolding of the 
extracellular matrix and with tropoelastin-bound FBLN5  (Noda et al., 2013).  LTBP4 is also a 
regulator of signaling by TGF-beta, an essential growth factor controlling the production of the 
ECM (Su et al., 2015). 
2.2.5 PYCR1-related cutis laxa 
Pyrroline-5-carboxylate reductase-1 (PYCR1)-related CL is also known as ARCL2B.  
Due to significant clinical overlap with aldehyde dehydrogenase-18 family member A1 
(ALDH18A1)-related CL, it has also been grouped with ARCL3A.  It is characterized by 
triangular facies and a progeroid appearance.  Poor growth, joint laxity, developmental delay and 
intellectual disability are also commonly reported (Dimopoulou et al., 2013; Reversade et al., 
2009).  Other features with predictive value but variable frequency in this form of CL include 
corneal clouding, agenesis of the corpus callosum, osteopenia, and athetoid movements.  
Mutations in exons at the beginning of the gene correlate with a milder phenotype than mutations 
in exons in the middle or end of the gene (Dimopoulou et al., 2013).  
PYCR1 is a mitochondrial enzyme which reduces pyrroline-5 carboxylate to proline 
while converting NAD(P)H into NADP+.  Proline is an amino acid abundant in elastin and 
collagen.  Fibroblast cells containing PYCR1 mutations exhibit increased rates of apoptosis with 
oxidative stress (Reversade et al., 2009). 
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2.2.6 ALDH18A1-related cutis laxa 
ALDH18A1-related CL is also called DeBarsy syndrome or autosomal recessive CL type 
3.  This condition shares significant phenotypic overlap with the proton-transporting adenosine 
triphosphatase V0 subunit A2 (ATP6V0A2)-related CL, and some individuals with a clinical 
diagnosis of DeBarsy syndrome have been identified as having mutations in ATP6V0A2.  
ALDH18A1 is most often an autosomal recessive condition, but recent reports describe several de 
novo cases associated with monoallelic mutations (Bhola et al., 2017; Fischer-Zirnsak et al., 
2015; Nozaki et al., 2016).  
Features commonly reported include lax skin that is prominent on hands and feet, 
developmental delay, microcephaly, inguinal hernia, translucent skin, congenital hip dislocation, 
joint laxity, hypotonia, brisk reflexes, cataracts, distal contractures, and failure to thrive.  
(Bicknell et al., 2008; Skidmore et al., 2011; Wolthuis et al., 2014; Zampatti et al., 2012).   
The ALDH18A1 gene codes for the mitochondrial enzyme delta 1-pyrroine-5-carboxylate 
synthase (P5CS).  P5CS is essential in the proline synthesis pathway, as well as in the synthesis 
of arginine in the gut.  P5CS deficiency leads to proline deficiency, which prevents collagen 
synthesis.  Proline is also required for the production of particular neuromoduators and 
supportive polypeptides for neuronal function (Pérez-Arellano, Carmona-Alvarez, Martínez, 
Rodríguez-Díaz, & Cervera, 2010). 
2.2.7 ATP7A-related cutis laxa 
Copper-transporting adenosine triphosphatase alpha (ATP7A)-related CL is also called 
occipital horn syndrome (OHS) or X-linked CL (XLCL), due to the gene’s location on the X 
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chromosome.  It was also previously known as Ehlers-Danlos type 9.  Low serum copper is a 
diagnostic marker for this form of CL (Kaler et al., 1994).  Mutations in ATP7A cause three 
disorders (in order of increasing severity); X-linked distal motor neuropathy, X-linked CL, and 
Menkes syndrome. 
Menkes syndrome is a neurodegenerative disorder with an onset in infancy, characterized 
by hypotonia, neurodevelopmental regression, seizures, arterial tortuosity, failure to thrive, and 
early mortality.  Individuals with Menkes syndrome also have sparse, brittle hair with a twisted, 
kinky texture (pili torti)  (Menkes, Alter, Steigelder, Weakley, & Sung, 1962). 
OHS is a milder form of Menkes syndrome (Das et al., 1995; Tümer & Horn, 1997).  In 
addition to loose skin, the pathognomonic feature is the presence of the so-called occipital horns, 
bilateral calcifications that form along the occipital ridge of the skull at the site of neck muscle 
attachments.   Other features that have been reported include bladder diverticula and diarrhea 
(Tsukahara, Imaizumi, Kawai, & Kajii, 1994).  Neurological manifestations include muscle 
weakness, dysautonomia, and mild intellectual disability (Wakai et al., 1993).  
ATP7A-related distal motor neuropathy is the least severe of the phenotypes associated 
with ATP7A mutations.  Its manifestations are limited to progressive weakness in distal limbs 
(Kennerson et al., 2010).   
ATP7A plays a role in the extracellular matrix and elastic fiber assembly through its role 
as a copper transporter.  Copper is essential for the activity of lysyl oxidase and lysyl oxidase-
like enzymes, necessary for crosslinking of monomers in elastin and collagen assembly (Alberts 
et al., 2002b).  Severity in ATP7A-related disorders appears to be correlated with levels of 
functional ATP7A protein produced, such that mutations resulting in production of some 
functional protein will cause milder forms of the disease (Møller, 2015).   For example, splice 
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site mutations that allow stable transcripts to be produced through exon skipping have been 
associated with OHS (Kaler et al., 1994). 
2.2.8 Geroderma Osteodysplasticum 
Geroderma osteodysplasticum (GO) is a form of CL caused by mutations in the GORAB 
gene (this gene is also known as SCY1-like 1 binding protein 1 (SCYL1BP1)).  The GORAB 
gene codes for a Golgi-associated protein that interacts with the G-protein Rab6.  GORAB, 
through its interactions with Rab6, participates in vesicular transport processes of the secretory 
pathway (Hennies et al., 2008).  The main distinguishing characteristics of GO are a progeroid 
appearance, drooping cheeks, maxillary hypoplasia and reduced bone density resulting in 
fractures of vertebrae and long bones (Kariminejad et al., 2017; Rajab et al., 2008).   
2.2.9  MACS syndrome 
Macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome is caused by 
mutations in Ras and Rab interactor 2 (RIN2), a Golgi protein that interacts with the G protein 
Rab5.  Rab5 participates in vesicular trafficking, and it is hypothesized that mutations in RIN2 
result in defects in vesicular transport of extracellular matrix components (Basel-Vanagaite et al., 
2009; Kimura, Sakisaka, Baba, Yamada, & Takai, 2006; Syx et al., 2010).  In addition to the 
distinguishing features of macrocephaly, alopecia, cutis laxa and scoliosis, individuals with 
MACS syndrome generally have significant developmental delay and intellectual disability, as 
well as coarse facial features (Syx et al., 2010). 
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2.2.10 ATP6V0A2-related cutis laxa 
ATP6V0A2-related CL is also known as autosomal recessive CL type 2A or Debre-type 
CL. As mentioned, there is significant phenotypic overlap between ATP6V0A2, ALDH18A1, and 
PYCR1-related CL subtypes, as well as with GO.  In addition, ATP6V0A2-related CL has a 
variable phenotype.  The milder forms have been clinically classified as wrinkly skin syndrome.  
The more severe forms fall under the clinical diagnosis of Debre type CL.  Generally, 
ATP6V0A2-related CL is characterized by wrinkled skin that becomes less wrinkled with age, 
and distinct craniofacial features including oxycephaly, delayed closure of anterior fontanels, 
downslanting palpebral fissures, a long philtrum, anteverted nares, and microcephaly (Van 
Maldergem et al., 2008).  Other features include joint laxity, congenital hip dislocation, hernias, 
hearing loss and ocular abnormalities, especially strabismus and myopia (Morava, Guillard, 
Lefeber, & Wevers, 2009).  Neurological involvement is common and can include seizures, 
developmental delay, intellectual disability, and abnormalities of cortical development such as 
cobblestone brain malformation (Fischer et al., 2012; Hucthagowder et al., 2009).  Pulmonary 
complications are uncommon.   One recent study found that out of 211 subjects who presented 
with cutis laxa and no pulmonary deficits, 24% of them had ATP6V0A2 mutations (Fischer et al., 
2012).   
ATP6V0A2-related CL is also a congenital disorder of glycosylation (CDG).  Morava et 
al. used transferrin and apolipoprotein C-III isoelectric focusing to identify N- and O-linked 
glycan biosynthesis defects in a cohort of CL patients fitting the phenotypic profile of 
ATP6V0A2-related CL (Morava et al., 2005). Although ATP6V0A2-related CL is currently the 
only CDG recognized as a cutis laxa subtype, other cases of CDGs with skin laxity have been 
reported.  These cases were associated with mutations in two Golgi-related genes for the 
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conserved oligomeric Golgi complex subunit COG7, and MAN1B1, a protein that targets 
misfolded proteins for degradation.  (Rymen et al., 2013; Wu et al., 2004).  
ATP6V0A2 also contributes to proper Golgi function.  The ATP6V0A2 gene encodes a 
component of a vacuolar ATPase (V-ATPase), the A2 subunit of the membrane-associated V0 
domain. The V-ATPase is an ATP-driven proton pump, and it functions to regulate the acidity of 
membrane-bound organelles such as the Golgi, lysosomes, endosomes, and vesicles (Hurtado-
Lorenzo et al., 2006).  Acidification is essential for both secretory and endocytic cellular 
functions (Forgac, 2007).  In ATP6V0A2-related CL, loss-of-function mutations are associated 
with abnormal protein trafficking that results in abnormal elastin production.  Fibroblasts still 
produce tropoelastin monomers, but there is reduced secretion of tropoelastin from the vesicles.  
As a result, ATP6V0A2 knockdown fibroblasts secrete low levels of elastin with abnormal 
aggregation of tropoelastin monomers in the Golgi apparatus (Hucthagowder et al., 2009; 
Kornak et al., 2008). 
2.2.11 Recently identified ATP6V-related cutis laxa subtypes 
Van Damme and colleagues recently described seven individuals with cutis laxa caused 
by mutations in ATP6V1E1 or ATP6V1A, subunits of the ATP hydrolytic domain of the vacuolar 
ATPase.  The phenotype in these individuals overlapped with that previously described for 
ATP6V0A2 mutations, including craniofacial features and musculoskeletal features such as joint 
laxity and congenital hip dysplasia.  Abnormal fat deposition, differences in skin features, and 
cardiovascular and pulmonary complications distinguished these forms of CL from ATP6V0A2-
related CL.  Like ATP6V0A2 mutations, ATP6V1 mutations cause abnormal Golgi trafficking.  
They also caused deficits in lysosomal function and were associated with impaired N- and O-
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type glycosylation.  Homology models predicted that the regions of the protein disrupted by the 
mutation were essential for the formation of stable interactions between subunits of the ATPase 
(Van Damme et al., 2017)   
2.3 ATP6V0A2 AND IMMUNE FUNCTION 
2.3.1 Possible roles for ATP6V0A2 in immune function 
At least three potentially intersecting pathways exist by which ATP6V0A2 function 
could impact the immune system.  First, endocytosis and destruction of invasive microbes and 
viruses depend on acidification of vesicles by ATPases.  Second, the acidification of intracellular 
and extracellular environments influences immune regulatory processes.  Finally, ATPase 
regulation of Golgi pH is important in the process of glycosylation, which is an essential 
mechanism for immune function.   
2.3.2 Vacuolar ATPases: structure, expression pattern, function 
The vacuolar ATPase is a molecular motor consisting of 13 subunits and two main 
domains, the V1 ATP-hydrolytic domain and the V0 membrane-associated domain.  The V1 
domain generates protons through the conversion of ATP to ADP.  The V0 domain contains 
multiple transmembrane helices that form a rotating ring.  The ring moves protons across the 
membrane. (Nishi & Forgac, 2000).  One of four possible “A” subunits is used in the V0 domain. 
The A2 subunit is expressed throughout the body in Golgi and endosomes, especially 
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macrophages, while A1, A3, and A4 have tissue-specific expression patterns involving cell 
surface interactions (Guillard et al., 2009; Toyomura et al., 2003; Uhlen et al., 2015).  The A2 
isoform was previously thought to be exclusively vacuolar, but certain membrane-associated 
roles have since been recognized (Kulshrestha et al., 2015; Ntrivalas, Gilman-Sachs, Kwak-Kim, 
& Beaman, 2007; Ota et al., 2013).   
The primary role of the vacuolar ATPase is in acidification of membrane-bound cellular 
compartments that are essential for secretory and endocytic cellular processes.  Membrane-bound 
organelles include the endoplasmic reticulum, the Golgi, secretory vacuoles, endosomes, and 
lysosomes.  The function of these organelles depends on the pH of their respective lumens which 
get progressively more acidic in the order listed above (Mellman, Fuchs, & Helenius, 1986).  In 
the lysosome, acidity permits activation of hydrolases that initiate degradation processes.  In 
receptor-mediated endocytosis, a change in pH stimulates conformational changes that allow 
ligand-receptor dissociation and receptor recycling (Mellman, 1992).  ATPases can also affect 
the acidity of extracellular environments, and so can also be found at the plasma membrane of 
certain cells such as osteoclasts, renal intercalated cells, and macrophages.  The ability of 
ATPases to regulate extracellular pH is also a reason that they are involved in tumorigenesis 
(Alzamora et al., 2013; Jaiswal et al., 2012; Kulshrestha et al., 2015; Nishi & Forgac, 2002; Ota 
et al., 2013; Toyomura et al., 2003) 
2.3.3 Glycoimmunology:  potential roles for ATP6V0A2 
Glycosylation is essential to cellular function.  Most proteins that are expressed on the 
surface of a cell or secreted are glycosylated, and disorders resulting in complete loss of glycans 
are incompatible with life. (Freeze, Chong, Bamshad, & Ng, 2014).  
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Glycosylation plays an essential role in both the innate and adaptive immune systems 
(Lyons, Milner, & Rosenzweig, 2015).   This relationship was first brought to light by studies 
showing changes in glycosylation patterns associated with arthritis (Parekh et al., 1985) and 
studies demonstrating that the presence of different levels of N-glycosylation on a critical 
fragment of immunoglobulin G (IgG) determine whether the IgG will produce a pro-
inflammatory or anti-inflammatory response (Kaneko, Nimmerjahn, & Ravetch, 2006; Schwab 
& Nimmerjahn, 2014).   
Because glycans are a highly variable group of molecules, they provide versatility in 
immune signaling and antigen recognition processes.  Many categories of immune cell receptors 
recognize glycans.  These include C-type lectins, which function to recognize and internalize 
pathogen-associated molecular patterns (PAMPS), siglecs, which recognize sialic acid-
containing glycans and which participate in immunological signaling, and galectins, which 
regulate signaling through cell surface interactions (Monticelli, Ferro, Jaeken, Dos Reis Ferreira, 
& Videira, 2016). 
Selectins are a category of immune cell receptors whose function depends upon glycan 
recognition.  Selectins are involved in facilitating the transfer of leukocytes from blood to 
infected tissue (extravasation).  Extravasation of leukocytes is a multi-stage process involving 
capture and rolling along the endothelial wall, activation, and adhesion at the appropriate site for 
exit into tissue.  Patterns of glycosylation on leukocytic selectin ligands determine the affinity of 
a particular selectin ligand for its complementary selectin on the endothelial wall of the vessel.  
High affinity will “capture” the selectin ligand (Ley, Laudanna, Cybulsky, & Nourshargh, 2007).   
Other categories of immune receptors that recognize glycans include the toll-like 
receptors and T cell receptors.  T cell receptors recognize even minor changes in glycosylation 
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patterns on cell surfaces, and can use them to create novel antigens for recognition by CD4+ and 
CD8+ T cells as well as by antibodies (Lyons et al., 2015).  Nucleotide oligomerization domain-
containing proteins 1 and 2 (NOD1 and NOD2) recognize peptidoglycans associated with 
pathogenic microorganisms (Philpott & Girardin, 2010).  Natural killer cells recognize 
glycolipids presented by CD1 cells (Zajonc & Girardi, 2015).     
There are extensive roles for glycosylation in immune function.  For example, Notch 
signaling pathways are involved in multiple processes, including the production of T and B 
lymphocytes, and also the development of the CD4 immune subset.  The particular ligands that 
bind to Notch, and therefore, the processes that are initiated, are determined by the identity of 
gylcans that are bound to Notch through the action of Fringe glycosyltransferases (Moloney et 
al., 2000).  As another example of the diverse roles for glycosylation in the immune system, 
studies of human milk have demonstrated that sialic acid-containing oligosaccharides found on 
milk proteins provide a first layer of defense when pathogens attack mucous membranes in the 
neonate (Newburg, 1999).   
At a systems level, a role for ATP6V0A2 in glycosylation-dependent immune function is 
suggested by the observation that patients with ATP6V0A2-related CL have abnormal N- and/or 
O-glycosylation patterns.   The same studies have shown defective trafficking of tropoelastin in 
ATP6V0A2-related CL (Fischer et al., 2012; Hucthagowder et al., 2009; Kornak et al., 2008).   
This trafficking defect was localized to abnormal Golgi structures in ATP6V0A2 mutant cells 
(Fischer et al., 2012; Hucthagowder et al., 2009).  In addition to a potential role in Golgi 
formation, maintenance of the appropriate acidity in the Golgi is essential for appropriate protein 
sorting and glycosylation (Klionsky, Nelson, & Nelson, 1992; Rivinoja, Hassinen, Kokkonen, 
Kauppila, & Kellokumpu, 2009). 
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Production of abnormal elastin fibers due to dysfunctional protein trafficking may 
provide an adequate explanation for the skin manifestations in the ATP6V0A2-related CL 
phenotype.  However, glycosylation functions regulated by ATPases that are involved in the 
formation and maintenance of the extracellular matrix may also play a role in the phenotype.  
Hinek and colleagues demonstrated that removal of sialic acid caps from glycoproteins in the 
extracellular matrix causes an increase in elastin deposition, and that a deficiency in the 
desialylating enzyme is linked to abnormal elastin deposition (Hinek, Pshezhetsky, von Itzstein, 
& Starcher, 2006).   
Additional glycosylation-dependent mechanisms may also be involved in the CL 
phenotype.  Hucthagowder et al. proposed reduced sialylation as a potential mechanism for the 
neurological sequelae of ATP6V0A2-related CL (Hucthagowder et al., 2009).  Xia and collagues 
described failure of brain vascular development in mice lacking O-type glycans due to abnormal 
interactions between ECM and endothelial cells (Xia et al., 2004).  Since many ECM proteins are 
glycosylated, Wopereis and colleagues suggested that N- and O- linked glycosylation deficits in 
ATP6V0A2 may underly the neurological aspects of the cutis laxa phenotype (Wopereis et al., 
2005).  It is also reasonable to suggest that glycosylation abnormalities could contribute to 
immune deficiencies.  
2.3.4 ATP6V0A2 regulation of immune response 
Several lines of experimental evidence suggest that ATP6V0A2 contributes to the 
regulation of immune responses.  First, ATP6V0A2 may have a direct role in the prevention of 
infection.  It is expressed in the neutrophil, where it is involved in exocytosis of granules 
containing antimicrobial molecules.  In experimental conditions stimulating an immune response 
27 
pathway in neutrophils, ATP6V0A2-containing granules were trafficked to the cell surface 
(Gilman-Sachs et al., 2015).      
Other roles for ATP6V0A2 in immune function are complex.  In some contexts, 
expression is inversely correlated with immune response, and in other contexts, expression is 
positively correlated with immune function. 
Reduced ATP6V0A2 expression can negatively impact the immune system.  A recent 
report from Udono and colleagues described a protective response known as the senescence-
associated secretory phenotype, triggered by reduced ATP6V0A2 expression.  Cell senescence is 
a generally adaptive phenomenon that arrests the cell cycle in at-risk cells.  The senescence-
associated secretory phenotype is a deleterious version of senescence, and it is triggered in 
response to cellular cues indicating that a cell’s DNA has been damaged.  Damaged DNA places 
a cell at risk for malignant transformation.  The senescence-associated secretory phenotype 
transforms senescent fibroblasts into pro-inflammatory cells and causes changes in the cell 
microenvironment.  These changes promote tissue repair in the short term, but have damaging 
consequences in the long term (Udono et al., 2015).    
Other studies indicate that increased ATP6V0A2 expression is associated with disease 
susceptibility.  Lee and colleagues provided evidence that ATP6V0A2 is involved in down 
regulation of the immune response.  They cloned cDNA of ATP6V0A2 (alternative name J6B7), 
and found that it produced a protein that suppressed lymphocyte reactions in vitro (Lee, Ghoshal, 
& Beaman, 1990). 
The A2 subunit of the V-ATPase is upregulated in mulitiple types of tumors.  
Immunohistochemical analysis of patient glioma tissue revealed upregulation of ATP6V0A2 
((Di Cristofori et al., 2015).  In another study, ATP6V0A2 was overexpressed at the surface of 
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ovarian tumor cells along with a stabilizing protein known to be localized at the leading edge of 
cancer cells (Kulshrestha et al., 2015).  Parmathy and colleagues demonstrated that ATP6V0A2 
associates with invasion assembly related proteins, and may promote migration of triple negative 
breast cancer cells.  Conversely, knockdown of ATP6V0A2 resulted in reduced tumor cell 
viability, increased cancer cell apoptosis and reduced cancer cell migration.  Altered interactions 
in the Notch signaling pathway may mediate these responses (Pamarthy et al., 2015). 
A2NTD is the N-terminal portion of the ATP6V0A2 protein and has been referred to as 
the RTF soluble fragment.  In monocytes, the a2NTD of monocytic ATP6V0A2 can be cleaved 
from the protein.  When the a2NTD is released, it behaves like a cytokine signal, and causes the 
monocyte to transform into a tumor associated macrophage, which promotes tumor growth and 
regulates inflammation in cancer (Boomer et al., 2001)  Cancer-related inflammation prevents 
tumor cells from being targeted by the immune system (Kwong, Gilman-Sachs, & Beaman, 
2011).  A2NTD induces immune cells to produce interleukin-1beta, which regulates 
inflammatory conditions (Ntrivalas, Derks, et al., 2007).  A2NTD also modulates production of 
and signaling functions of immune cytokines (Boomer et al., 2001; DuChateau, Lee, Westerman, 
& Beaman, 1999; Ntrivalas, Gilman-Sachs, et al., 2007).  As a result, researchers are examining 
the potential of V-ATPase inhibitors as cancer therapeutic agents (Izumi et al., 2003). 
The acidic extracellular environment generated by membrane ATPases promotes tumor 
growth through activation of proteases that dismantle the extracellular matrix (Bergamaschi et 
al., 2008).  In addition, the increased acidity in tumor cells allow them to escape immune 
mediated apoptosis (Ishisaki, Hashimoto, Amagasa, & Nishihara, 1999).  Conversely, inhibition 
of ATPases induces apoptosis in tumor cells (Aiko et al., 2002; De Milito et al., 2007).   
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In mammalian pregnancy, maternal immune responses must be adjusted to permit 
tolerance of the fetus.  ATP6V0A2 participates in the regulation and coordination of pregnancy-
related immune responses.  Successful implantation during pregnancy depends on signaling 
between “host” (mother) and “allograft” (fetus) (Aplin & Kimber, 2004; Jaiswal et al., 2013).  
During bovine embryonic implantation, the expression of A, B, and C subunits of the vacuolar 
ATPase is increased (Skinner, MacLaren, & Wildeman, 1999).  Levine and colleagues later 
characterized the role of ATP6V0A2 in implantation.   Implantation requires an inflammatory 
response and subsequent vascularization.  The authors showed that the inflammatory response 
was triggered through a multi-step process, in which ATP levels in the cell resulted in the release 
of the pro-inflammatory cytokine IL-1beta and the promotion of the inflammatory response 
(Levine, Derks, & Beaman, 2005).   
ATP6V0A2 is expressed in sperm and contributes to the acidity of seminal fluid.  Fertile 
men have higher sperm ATP6V0A2 expression levels than infertile men, and motile sperm have 
higher ATP6V0A2 expression levels than immotile sperm (Ota et al., 2013).  Jaiswal and 
colleagues reported that capacitated sperm released cleaved a2NTD in the uterus, causing 
increased expression of pro-inflammatory immune molecules (Jaiswal et al., 2012).  Studies in 
HIV-infected individuals demonstrated increased ATP6V0A2 (alternative name RTF) expression 
that was positively correlated with the degree of immune deficiency (DuChateau et al., 1999).  
Boomer and colleagues demonstrated involvement of ATP6V0A2 (alternative name regeneration 
and tolerance factor RTF) in protecting cells from immune attack.  They hypothesized that 
ATP6V0A2 established immunological tolerance through clonal anergy, the inactivation of self-
reactive lymphocytes (Boomer et al., 2001).     
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Because functional evidence exists for both supportive and deleterious roles for 
ATP6V0A2 in immune function, it is likely that an ATP6V0A2 mutation can have different 
effects on different cellular processes.  This could occur through the stimulation of different 
signaling pathways (Alberts et al., 2002a).  Regulatory mechanisms within the same system can 
also produce a paradoxically identical effect when the same gene is upregulated or 
downregulated (Feng, 2012; Wang et al., 2014).  Wang et al described a protein SRPK1 that is 
needed for recruitment of a phosphatase that downregulates consitutitive activation of the 
oncogenic protein Akt.  They demonstrated that overexpression of SRPK1 caused squelching of 
the phosphatase.  On the other hand, reduced expression of SRPK1 prevented recruitment of the 
phosphatase.   Changes in either direction of expression caused an increase in oncogenic activity 
(Wang et al., 2014).  It is possible that the immune-suppressive upregulation of ATP6V0A2 
reflects a similar phenomenon.  Further functional immunological studies may elucidate the 
mechanisms of action for ATP6V0A2.(Lyons et al., 2015) 
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3.0  MANUSCRIPT:  INCREASED INCIDENCE OF INFECTIONS IN ATP6V0A2-
RELATED CUTIS LAXA 
3.1 BACKGROUND 
Cutis laxa (CL) is a family of connective tissue disorders affecting approximately 300 
families worldwide.  The most prevalent feature in CL is loose, wrinkled, skin, conferring an 
aged appearance to individuals affected by this condition (Berk et al., 2012) .  There is variable 
systemic involvement, and the constellation of symptoms seen in a particular individual is 
largely dependent on the underlying genetic cause of the condition.  Over twelve CL-causing 
genes have been identified, and one of these is ATP6V0A2 (Kornak et al., 2008).  This gene 
codes for the A2 subunit of the vacuolar-ATPase’s V0 domain.  Vacuolar ATPases are proton 
pumps that are responsible for the acidification of membrane-bound organelles such as the ER, 
Golgi, endosomes, lysosomes, and vesicles.    
ATP6V0A2-related CL is caused by homozygous or compound heterozygous mutations in 
the ATP6V0A2 gene.  It has been associated with generalized skin laxity, characteristic 
craniofacial features including delayed fontanel closure, downslanting palpebral fissures and a 
broad nasal bridge, musculoskeletal features including joint laxity, congenital hip dislocation and 
hernias, and neurological involvement including developmental delay, seizures, and brain 
malformations (Fischer et al., 2012). 
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The mutations that cause ATP6V0A2-related CL disrupt the process of elastic fiber 
production (Hucthagowder et al., 2009).  Normally, tropoelastin monomers are trafficked from 
the Golgi to the cell surface and are secreted into the extracellular space.  There, tropoelasin 
monomers aggregate through a pH and temperature-driven process called coacervation, and are 
crosslinked by the oxidation of lysyl residues to form the elastin polymer.  Through the actions 
of fibulins, the elastin is deposited onto microfibrils and is incorporated into the extracellular 
matrix (Baldwin et al., 2013). 
In ATP6V0A2-related CL, elastic fiber formation is dysfunctional due to abnormalities in 
the Golgi trafficking process.  Experiments in fibroblasts containing patient-derived mutations in 
the ATP6V0A2 gene demonstrated multiple abnormalities in the elastin production pathway.  
These included fragmented Golgi, swollen Golgi fragments holding large amounts of 
tropoelastin monomers, increased formation of abnormal tropoelastin aggregates, reduced 
formation of elastin polymers, and increased apoptosis rates (Fischer et al., 2012; Hucthagowder 
et al., 2009).  Abnormal Golgi, abnormal aggregation of tropoelastin, and dysfunction in the 
secretory process can all be linked to dysregulation of pH. 
ATP6V0A2-related CL is also recognized as a congenital disorder of glycosylation 
(CDG), (Morava et al., 2005).  A subset of CDGs have significant immune involvement, and 
susceptibility to infection may also be increased for individuals with ATP6V0A2-related CL.  
Glycosylation defects can have a negative impact on immunity because many aspects of immune 
function are glycosylation-dependent.  Glycans are a highly variable group of molecules that 
provide versatility in immune signaling and antigen recognition processes, and many categories 
of immune cell receptors recognize glycans (Monticelli et al., 2016).  
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Shaw and colleagues recently identified an individual with Epstein-Barr-associated 
smooth muscle tumors, which are seen in conditions of immune deficiency such as AIDS 
(Deyrup et al., 2006).  This individual’s presentation also included CL, aortic root dilation, 
presumed fetal alcohol syndrome, intellectual disability and developmental delay.  
Immunological investigations determined that a lack of natural killer cells (NK) was the 
underlying mechanism for the patient’s immune deficiency (Shaw et al., 2012).  Exome 
sequencing revealed an ATP6V0A2 mutation (Orange, personal communication).    
This observation suggests that the ATP6V0A2-related CL phenotype may include immune 
deficits.  However, because immunological deficits have also been reported as a consequence of 
fetal alcohol syndrome (Johnson, Knight, Marmer, & Steele, 1981), further investigation is 
warranted.  Immunological function in CL has not been studied, but it would be of clinical 
importance to characterize this aspect of CL involvement.  To investigate possible 
immunological consequences of ATP6V0A2 mutations, we administered an infection history 
questionnaire to individuals with ATP6V0A2-related CL, their unaffected first-degree relatives, 
and, as a control, individuals with ELN-related CL.  
Using the infection history questionnaire data, we calculated an age-weighted infection 
score for each participant.  We compared the scores for each group and found that individuals 
with ATP6V0A2-related CL had higher infection scores than individuals in either control group, 
suggesting that there is an as-yet-unrecognized immune component to the ATP6V0A2-related CL 
phenotype.   
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3.2 SUBJECTS AND METHODS 
3.2.1 Study Participants 
All study participants gave their informed consent for participation in a study examining 
genotype-phenotype relationships in individuals with CL and in first degree relatives of 
individuals with CL (CL study).  All procedures were approved by the Institutional Review 
Board of the University of Pittsburgh’s Office for the Protection of Human Subjects in Research 
(Appendix A).   
Participants in the CL study were volunteers who were recruited through their physicians, 
or volunteers who contacted the study after finding our study information online 
(www.cutislaxa.pitt.edu).  The Urban lab is the only US research group that studies CL, and 
because of this, physicians and patients contact the study with requests to enroll.  After initial 
contact, the participants were screened by telephone to determine if they met study criteria 
(Appendix D).  Individuals met study criteria if they exhibited multiple skin features such as lax 
or prematurely aged skin, reported other systemic features such as arterial tortuosity, or had a 
confirmed genetic diagnosis of CL through testing by an outside lab. The first-degree relatives of 
these individuals were also eligible to participate in the study.  As part of our study procedures, 
we screened participants’ DNA for mutations in known CL causing genes using Sanger 
sequencing.  For participants with a genetic diagnosis identified by an outside lab, we confirmed 
the diagnosis through sequencing.  We obtained demographic and clinical information for each 
participant through a CL clinical questionnaire that was filled out by a physician (Appendix C). 
A subset of study participants volunteered to attend a CL research clinic held at the 
University of Pittsburgh.  We contacted individuals with ATP6V0A2-related CL and invited 
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them to the clinic.  The remainder of the clinic participants contacted the study with a request to 
attend.  Testing included a physical, a genetic exam, a blood draw, a skin biopsy, pulmonary 
function testing, echocardiogram, chest CT scans, facial imaging, and skin and vascular elasticity 
measurements.  The clinic also included a meeting with the PI and a patient support group and 
information session.  
3.2.2 Methods 
We compiled data from four participants with ATP6V0A2-related CL.  These individuals 
had homozygous or compound heterozygous mutations in the ATP6V0A2 gene.  We also 
collected data from four unaffected relatives, each with a single mutation in the ATP6V0A2 gene.  
As another comparison, we collected infection history data from two participants with elastin 
(ELN)-related CL.  ELN-related CL is an autosomal dominant condition caused by a mutation in 
the ELN gene.  It is not known to be associated with immune deficiency.   Table 1 contains 
mutation information for each participant. 
 
 
36 
Table 1.  Mutation data 
 
 
 
Clinical characteristics of the participants were collected as a part of their participation in 
CL research clinics organized at the University of Pittsburgh.  As part of the CL research clinic, 
each participant underwent a clinical genetics assessment including a physical exam.  The study 
team also reviewed participants’ relevant medical records.  Results of the examination and 
details of the family history were entered in a cutis laxa clinical questionnaire (Appendix C). 
Clinical photographs were taken to document relevant anatomical features. Additional tests 
performed during the clinic included lung function testing, echocardiography and 3-dimensional 
facial imaging.  
! ! ! Mutation!1! Mutation!2!
ID! GENE! REFERENCE!
SEQUENCE!
cDNA! AMINO!ACID!
CHANGE!
cDNA! AMINO!
ACID!
CHANGE!
7093% ATP6V0A2% NM_012463% c.397_398insCATGCTGA%%% p.R133fs*3% c.2466_2470delGGTAG% p.W822*%
7226% ATP6V0A2% NM_012463% c.1351C>T% p.R451W% c.2040C>A% p.C680*%
7264% ATP6V0A2% NM_012463% c.1351C>T% p.R451W% C% C%
7263% ATP6V0A2% NM_012463% c.2040C>A% p.C680X% C% C%
7346% ATP6V0A2% NM_012463.3% c.78dupC% p.S27Qfs*28% C% C%
7363% ATP6V0A2% NM_012463.3% c.78dupC% p.S27Qfs*28% c.78dupC% p.S27Qfs*28%
7364% ATP6V0A2% NM_012463.3% c.600delC% p.I201Sfs*20% C% C%
7365% ATP6V0A2% NM_012463.3% c.600delC% p.I201Sfs*20% c.2176C5C>G% intronic%
7342% ELN% NM_001278939.1% c.1418G>A% p.G473D% C% C%
7197% ELN% NM_001278939.1% c.5C>A% p.A2E% C% C%
%
Shaded%rows%indicate%individuals%with%cutis%laxa%
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We administered an infection history questionnaire to clinic participants (Appendix B). 
This questionnaire was modified from a questionnaire used by the laboratory of Jordan Orange.  
The modifications were designed to make it easier for patients to complete the questionnaire 
without the help of a clinician.  The questionnaire asked whether participants had ever 
experienced a particular infection type.  If the infection was a bacterial or fungal infection, or 
other infection that could be experienced more than once, we asked the participants to provide a 
frequency estimate (yearly or lifetime) for that type of infection.  Infection types included viral 
infections such as varicella, measles, and stomach flu, bacterial infections such as strep throat 
and otitis media, and fungal infections such as yeast infections and ringworm. For infection types 
having the potential for recurrence, we asked participants to provide a lifetime or annual 
frequency.   To minimize errors caused by self reporting, if a participant indicated that he or she 
had experienced a particular infection, study staff contacted that participant by phone to follow 
up with questions such as, “Was this infection confirmed by testing?” 
To summarize each participant’s data across infection types, we calculated a total 
infection score weighted by participant age.  We devised this novel method in order to be able to 
quantify the infection rate among our participants.  Quantification permitted us to capture subtle 
differences between study groups.  The infection score incorporated two factors; the number of 
different types infections that a person experienced, and the frequency of infections.  First, we 
assigned a score for each infection type.  If a participant experienced an infection type between 
one and three times, we used a score of one for that infection type.  If a participant experienced 
an infection type more than three times, we used a score of two.  We then summed scores across 
all infection types to create a total infection score for each participant.  Table 2 shows total 
number of infection types as well as the total infection score for each participant. 
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Table 2.  Infection history data 
 
 
 
We modified the scoring criteria for infection types in the following cases:  If a 
participant gave a numerical range for incidences of an infection type, we used the lowest 
reported number.  If a participant reported experiencing an infection “a few” times, we used a 
score of one.  If a participant reported an infection as “ongoing, we used a score of one.  If a 
! Participant)ID)
)Infection)Type) 7363) 7365) 7264) 7263) 7346) 7093) 7226) 7364) 7197) 7342)
Oral!herpes! !! !! !! !! !! !! !! !! !! !!
CMV,!EBV,!
mononucleosis! !! !! !! !! +! !! !! !! !! +!
Varicella! +! +! +! +! !! +! !! !! !! +!
HPV! !! !! !! +! !! +! !! !! !! !!
Roseola,!human!
herpes!virus,!other!
DNA!virus! !! !! !! !! !! !! !! !! !! !!
Flu,!cold,!stomach!
flu! +! +! !! !! ++! +! +! +! +! !!
Flu!vaccine!
reaction! !! !! !! !! +! !! !! !! +! !!
Mycobacteria,!
listeria,!atypical!
intracellular!
bacteria! !! !! !! !! !! !! !! !! !! !!
Strep!throat! +! +! +! ++! ++! +! !! !! !! !!
Urinary!tract!
infection! +! !! !! ++! ++! +! !! !! !! !!
Conjunctivitis! !! +! !! +! +! +! !! !! !! +!
Otitis!media! ++! +! +! !! ++! +! ++! +! !! !!
Pneumonia*! +! !! !! !! ++! +! ++! +! !! !!
Staph!aureus!skin!
infection! !! !! +! +! !! !! !! !! !! !!
Bronchitis! +! !! ++! ++! ++! ++! !! !! !+! !!
Bacterial!vaginosis! !! !! !! !! !! +! !! !! !! !!
Ringworm! +! +! !! !! +! !! !! !! !! ++!
Yeast!infection! !! !! !! +! +! ++! !! !! +! !!
Toenail/fingernail!
infections! !! !! !! !! !! ++! !! !! !! ++!
Total)number)of)
infection)types) 8! 6! 5! 8! 11! 12! 3! 3! 4! 5!
Total)infection)
score) 9! 6! 6! 11! 17! 15! 5! 3! 4! 7!
+!=!1!to!3!times,!++!=!!>3!times,!!
*!++!!=!>1!time!!
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participant reported experiencing an infection “many” times, we used a score of two.  If a 
participant reported experiencing pneumonia two or more times, we used a score of two for the 
pneumonia infection type.   
We weighted each total infection score by participant age.  To do this, we divided each 
participant’s total infection score by years of life.  We chose this approach because two 
participants with ATP6V0A2 were under 10 years old, and our study group lacked age matched 
comparisons in the unaffected heterozygote or ELN groups.  We weighted infection scores by 
age to account for the fact that younger participants would naturally be exposed to fewer 
infectious agents than older participants.  The unweighted total infection scores of the child 
participants tended to be lower than adult scores in our study sample (Figure 1). 
 
 
Figure 1.  Age vs. total infection score (unweighted) 
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We calculated group means for the ATP6V0A2 group, the unaffected heterozygous 
relative group, and the ELN group.  We compared the group means with t-tests.  For each 
comparison, a variance ratio test confirmed that the samples did not have unequal variance.  We 
also performed power calculations for our t-tests.  All statistics were calculated using Stata 
software. To address concerns about the small size of this sample and the need for age-weighting 
to include child participants, we performed additional statistical analyses on a data set that 
excluded child participants.  
3.3 RESULTS 
Three of the four participants with ATP6V0A2-related CL had compound heterozygous 
mutations, and one had a homozygous mutation (Table 1).  A total of seven different mutations 
were observed; two nonsense, one missense, three frameshift, and one splice site mutation, 
consistent with prior reports (Kornak et al. 2008, Hucthagowder et al. 2009).  Two of these 
mutations from a single participant (c.397_398insCATGCTGA, c.2466_2470delGGTAG) have 
been described previously (Hucthagowder et al., 2009).  One additional mutation had been 
previously described in a patient who was not part of this study (c.600delC) (Fischer-Zirnsak et 
al., 2015). Out of the six mutations not involving a splice site, three were located in the long 
initial cytoplasmic region of the protein.  The other three mutations were located within or near 
transmembrane domain regions spread across the protein (Figure 2) (The UniProt Consortium, 
2017).  These observations are consistent with a previous report, in which approximately one 
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third of identified mutations were located in the initial cytoplasmic domain, and most of the 
remaining mutations were in or near transmembrane domains (Hucthagowder et al., 2009).  
Transmembrane domains appear to be essential for APT6V0A2 function (Hucthagowder et al., 
2009; Kornak et al., 2008).   
The software prediction algorithm MutationTaster predicted all but one variant to be 
pathogenic.  The splice site mutation (c.2176-5C>G) was predicted to be a polymorphism, but 
with the potential to affect splicing. The identification of the variant in a patient suggests that 
deleterious splicing abnormalities do occur.  Another variant, c.78dupC, had previously been 
reported as pathogenic in the ClinVar database.  MutationTaster reported that the single missense 
mutation (c.1351C>T, p.R451W) was conserved or partly conserved in all species having a 
homologue to ATP6V0A2.  PolyPhen2 and SIFT also predicted the R451W amino acid 
substitution to be disease causing.    
 
    
 
Figure 2.  Location of mutations on ATP6V0A2 protein (adapted from Hucthagowder et al. 2008) 
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Three parents and one sibling were included in the study as controls (Figure 3, Table 2).  
All four were unaffected heterozygous mutation carriers.  As cutis laxa controls, two individuals 
with heterozygous elastin mutations were included.  Both of these participants had missense 
mutations (Table 1).  
 
 
 
Figure 3.  Familial relationships between individuals with ATP6V0A2-related CL and unaffected 
relatives 
 
 
 The ATP6V0A2-related CL group was composed of two adult females, one seven-year 
old boy, and one two-year old female (Table 3).  All participants had dysmorphic features.  
Among the participants with ATP6V0A2 mutations, at least ¾ exhibited a history of congenital 
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skin laxity, patent anterior fontanel, blue sclera, developmental delay, joint laxity, or abnormal 
pulmonary function testing.  At least 2/4 reported a history of prematurity, low birth weight, 
microcephaly, eye alignment abnormalities, hearing loss, seizures, or hernia (Table 3). These 
findings are consistent with previous observations with the exception of pulmonary deficits 
which have not been reported as a characteristic feature of ATP6V0A2-related CL (Fischer et al., 
2012). 
 
Table 3.  Clinical characteristics of individuals with cutis laxa 
ID# 7093# 7346# 7364# 7226# 7342# 7197#
ATP6V0A2#mutation# +# +# +# +# 4# 4#
ELN#mutation# 4# 4# 4# 4# +# +#
Age#at#exam# 28# 32# 2# 7# 67# 70#
Gender# F# F# F# M# M# F#
Prematurity# *# *# +# +# ?# ?#
Low#birth#weight# *# *# +# +# ?# *#
Congenital#skin#findings# +# +# +# +# *# *#
Patent#anterior#fontanel# +# +# *# +# *# *#
Dysmorphic#features# +# +# +# +# +# +#
Microcephaly# *# *# +# +# *# *#
Myopia# *# *# *# +# +# +#
Eye#alignment#abnormalities# *# *# +# +# *# *#
Blue#sclera# +# *# +# +# *# *#
Hearing#loss# *# +# *# +# +# *#
Hoarse#voice# +# *# *# *# *# +#
Developmental#delay# +# +# +# +# *# *#
Seizures# +# *# *# +# *# *#
Hip#dysplasia# *# *# +# *# *# *#
Joint#laxity# +# +# +# ?# *# *#
Hernia# *# *# +# +# *# +#
Aortic#aneurysm# *# *# +# *# +# *#
Small#left#ventricle# *# +# *# *# *# +#
Abnormal#pulmonary#function# +# +# n/a# +# +# +#
Asthma/emphysema# +# +# *# +# *# +#!
44 
The infection questionnaire results (Table 2) revealed severe cold/flu episodes, strep 
throat, urinary tract infections (UTIs), conjunctivitis, otitis media (OM), pneumonia, bronchitis, 
and yeast infection in the two adult participants with ATP6V0A2-related CL.  The two juvenile 
patients with ATP6V0A2-related CL reported severe cold/flu episodes, OM, and pneumonia.  The 
adult unaffected relatives collectively reported varicella, HPV, severe cold/flu episodes, strep 
throat, UTIs, conjunctivitis, OM, pneumonia, staph infection of the skin, bronchitis, ringworm, 
and yeast infections.   The adults with ELN-related CL reported cytomegalovirus, varicella, 
severe cold/flu episodes, flu vaccine reaction, conjunctivitis, bronchitis, ringworm, yeast 
infection, and toenail/fingernail infections. 
The adult participants with ATP6V0A2-related CL had the highest unweighted total 
infection scores (average number of infection types = 16) (Figure 1, Table 2).   They also 
reported the largest variety of infection types (average number of infection types = 11.5) (Table 
2).  The child participants with ATP6V0A2-related CL reported the smallest variety of infection 
types (average number of infection types = 3, Table 2), and their unweighted total infection 
scores were among the lowest (average total infection score = 4, Table 2).  But when total 
infection scores were weighted by age, the child participants with ATP6V0A2-related CL had 
higher scores than the unaffected heterozygous relatives and the participants with ELN-related 
CL (Figure 4). 
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Figure 4.  Age-weighted total infection score for each participant 
 
 
Total age-weighted infection scores (Figure 4) were the highest in ATP6V0A2-related CL 
participants, and ranged from 0.53 to 0.75.  The heterozygous relatives’ scores ranged from 0.12 
to 0.26, and the ELN-related cutis laxa scores ranged from 0.07 to 0.12.  
The mean age-weighted infection score (Figure 5) for participants with ATP6V0A2-
related cutis laxa (ATP6 aff) was significantly higher than the mean score for unaffected 
relatives with heterozygous ATP6V0A2 mutations (ATP6 het) (Pr(ATP6 aff > ATP6 het) = 
0.0107) (Fig 5).  In addition, the age-weighted mean infection score of participants with 
ATP6V0A2-related cutis laxa was significantly higher than that of participants with ELN-related 
cutis laxa (ELN aff)  (Pr(ATP6 aff > ELN aff) = 0.0108) (Figure 5, Table 4). 
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We also examined data calculated using an age-adjustment by decades of life.  We hoped 
this approach would mitigate any over-weighting of the young participants’ infection scores that 
occurred as a result of age-weighting by year.   The age adjustment by decades of life 
comparisons, while still showing significant differences between groups, did not have as much 
statistical power as the age adjustment by years of life (Table 5).    
We also analyzed the data without including the child participants, thus eliminating the 
need for the age-weighting procedures.  Despite the smaller sample size, we still found that 
individuals with ATP6V0A2-related CL had higher total infection scores than unaffected 
heterozygous relatives (p=0.0072) or individuals with ELN-related CL (p=0.0171) (Figure 6).  
Calculated power for both comparisons exceeded 0.80 (Table 5).      
 
 
 
Figure 5. Between-group comparison of age-weighted mean infection scores 
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Figure 6.  Between group comparisons of mean infection scores (adults only) 
 
 
Table 4.  Statistical test results (all subjects) 
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Table 5.  Statistical test results (adults only) 
 
 
3.4 DISCUSSION 
In this study, we characterized infection history among individuals with ATP6V0A2-
related CL.  We also compared infection variety and infection rate to individuals with 
heterozygous mutations in ATP6V0A2 and to individuals with another type of cutis laxa, ELN-
related CL.  We hypothesized that the ATP6V0A2 group would have a higher rate of infections 
than the comparison groups of unaffected heterozygous relatives and individuals with ELN-
related CL.   
Our study group included four individuals with ATP6V0A2 mutations, all of whom had 
experienced multiple categories of infections.   Adult participants with ATP6V0A2-related CL 
reported a wider variety of infection types and more frequent infection rates than their 
heterozygous unaffected relatives.  Between-group comparisons of the mean age-adjusted 
infection scores demonstrated that individuals with ATP6V0A2-related CL experienced more 
infections per year of life than individuals with a single ATP6V0A2 mutation or individuals with 
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ELN-related CL.  This suggests a previously unrecognized deficit in immune function for 
individuals with ATP6V0A2-related CL. 
ATP6V0A2-related CL is a multi-systemic disorder, with features that frequently affect 
the skin, the musculoskeletal, pulmonary, digestive, and genitourinary systems (Fischer et al., 
2012).  Some features in all of these systems could be explained sufficiently by structural 
abnormalities in connective tissue caused by abnormalities in the Golgi and abnormalities in 
trafficking elastic fiber proteins (Hucthagowder et al., 2009).   However, some features of 
ATP6V0A2-related CL, such as neurological abnormalities, are likely to have a complex 
pathogenesis incorporating abnormalities in extracellular matrix, glycosylation, and cellular 
trafficking processes (Van Maldergem et al., 2008) (Guillard et al., 2009).   The immune 
deficiencies suggested by our data are also likely to have a complex pathogenesis.   
Both glycosylation and cellular trafficking processes have the potential to impact 
multiple body systems, and could be involved in features of ATP6V0A2-related CL.  
Glycosylation can have effects on development of brain, bones, and organ systems through its 
regulation of signaling pathways (Harper, Yuan, Tan, Visan, & Guidos, 2003; Ishikawa et al., 
2005).  There are also many potential roles for glycosylation in immune function.  Many 
receptors in the immune system recognize glycosylated molecules.  These include C-type 
lectins, which function to recognize and internalize pathogen-associated molecular patterns 
(PAMPS), siglecs, which recognize sialic acid-containing glycans and which participate in 
immunological signaling, and galectins, which regulate signaling through cell surface 
interactions (Monticelli et al., 2016).     
Symptoms of ATP6V0A2-related CL could also be caused by abnormalities in vacuolar 
function and cellular trafficking processes.  ATPases regulate pH of notochord vacuoles, which 
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participate in body axis elongation in early stages of vertebrate embryonic development (Ellis, 
Bagwell, & Bagnat, 2013).  Trafficking is also an essential component of normal neuronal 
growth, differentiation and development (Chapleau, Larimore, Theibert, & Pozzo-Miller, 2009).    
To characterize the nature of the immune deficiency in our patient population, our 
collaborators performed immunological analyses on peripheral blood mononuclear cells 
collected from the individuals in our study group.  Their experiments showed that natural killer 
(NK) cells were negatively impacted by mutations in ATP6V0A2.  Natural killer cells are part of 
the innate immune system, and are best known for their role in eliminating viral pathogens and 
tumor cells (Orange, 2013). The Orange group found that peripheral blood samples of 
individuals with ATP6V0A2-related CL contained a smaller number of NK cells.  The NK cells 
that were present expressed markers that were associated with inhibition and immaturity, and 
they expressed lower levels of markers associated with maturity and effector functions.  The 
cytotoxicity of the NK cells was also diminished.  Together, these data suggest that NK cell 
development and maturation may be impacted by the loss of ATP6V0A2 (Watkin et al., 2017).   
Reduced NK cell cytotoxicity has been reported in multiple conditions including 
myelodysplastic syndromes (Hejazi et al., 2015), the immune disorder Hermansky-Pudlak 
syndrome subset 2 (Fontana et al., 2006), familial haemophagocytic lymphohisiocytosis subset 
3 (Marcenaro et al., 2006), cancer (Hodge et al., 2014), and endometriosis, which is also 
hypothesized to have an immune component (Oosterlynck, Cornillie, Waer, Vandeputte, & 
Koninckx, 1991). NK cell reduction has been reported in patients with rheumatoid arthritis, 
scleroderma, insulin-dependent diabetes, and psoriasis (Koreck et al., 2002; Sumida et al., 1995; 
Wilson et al., 1998; Yanagihara, Shiozawa, Takai, Kyogoku, & Shiozawa, 1999).  A recent 
study described a mutation in MCM4 associated with systemic manifestations such as adrenal 
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insufficiency, growth deficiency, and NK cell deficiency.  The mutation caused a failure in the 
promotion of DNA replication and lack of maturation in NK cells (Gineau et al., 2012).  An 
interaction between ATP6V0A2 (or its downstream functions) and the MCM4 system, or a 
similar system yet to be identified, could affect the NK phenotype (Orange, 2012).  Future work 
may elucidate the role of ATP6V0A2 in NK cell development and maturation as well as the 
mechanisms leading to dysfunction in these processes.   
This report has several limitations that should be addressed in future studies.  First, it will 
be necessary to confirm and expand our analysis with a larger sample size.  Although the 
statistical power of our analyses were sufficient to give us confidence in the results, our results 
must be interpreted with caution due to the small numbers of subjects.  A larger sample may also 
allow us to assess susceptibility in CL to less prevalent and later onset consequences of NK cell 
deficiency, such as cancer.   
Second, it would be desirable to have age-matched controls for our child participants with 
ATP6V0A2-related cutis laxa.  We found that our youngest participants had few types of 
infections, resulting in lower unweighted infection scores.  When data was adjusted for age, child 
participants with ATP6V0A2-related CL had higher infection scores than unaffected relatives.  
This approach has the disadvantage of potentially overweighting the immune scores for younger 
participants.  However, the unweighted scores of the adult ATP6V0A2-related CL participants 
were significantly higher than the scores of the adult ELN-related CL participants, who were also 
older.  This indicates that the relationship between mutation status and infection score was 
unchanged by weighting. 
Third, it would be preferable to obtain additional data from the ELN-related CL control 
comparison group.  One reason for this is that neither member of the ELN group had the 
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“classical” form of the CL-causing ELN mutation.  This classical mutation is a frameshift at the 
end of the gene, which results in translation of an elongated elastin precursor that cannot form 
normal elastin polymers (Callewaert et al., 2011).  The participants in this category were older 
than any of the other participants, which is another potential age-related confounding factor.  
However, it is relevant to note that the older age of the ELN-related CL group does not appear to 
have translated into higher infection scores for these individuals, as might be expected if our 
infection scores were simply a result of having more years in which to be exposed to pathogens.  
Other future research directions would be to examine genotype-phenotype relationships 
between particular mutations and immune function.  To date, weak genotype-phenotype 
relationships have been identified ATP6V0A2-related CL with missense mutations resulting in 
slightly less severe disease (Hucthagowder et al., 2009).  Although our study sample was small, 
it is of note that the adult heterozygous participant with the highest unweighted infection score 
was the mother of the child with the higher unweighted infection score (Table 2, Figures 1, 3).  It 
is possible that particular mutations have a higher impact on immune function, and that among 
unaffected heterozygous relatives, a single copy of a particular mutation may be more 
detrimental to immune function.  Studies focused on the cellular consequences of particular 
mutations may shed light on this question. 
Van Damme and colleagues recently described seven individuals with cutis laxa caused 
by mutations in ATP6V1E1 or ATP6V1A, subunits of the ATP hydrolytic domain of the vacuolar 
ATPase.  The phenotype in these individuals overlapped with that previously described for 
ATP6V0A2 mutations.  Homology models predicted that the regions of the protein disrupted by 
the mutation were essential for the formation of stable interactions between subunits of the 
ATPase (Van Damme et al., 2017).  Interestingly, other proteins that are involved in assembly of 
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subunits, such as ATP6AP1, have been implicated in immune deficiency (Jansen et al., 2016).  
The use of homology models may be similarly useful in elucidating the pathophysiology of 
ATP6V0A2-related CL.  
We would also like to expand our analysis to individuals with other forms of CL, to see if 
there are any other forms that have an unrecognized susceptibility to infections.  It is also 
possible that some of the genetically undiagnosed cases of CL have an immune component.  If 
true, infection history review could provide clues to diagnosis.  Infection history assessment also 
has the potential to provide guidance when planning genetic testing for individuals in whom an 
autosomal recessive form of CL is suspected.  
Understanding the increased susceptibility to infection in ATP6V0A2-related CL has the 
potential to change treatment for individuals with this rare condition.  It may be important for 
these individuals to receive regular immunizations against pathogens with available vaccines that 
are optional in the general population, such as the flu, Pneumococcus, and HPV vaccines. 
Prophylactic antibiotic therapy under certain conditions, and/or aggressive treatment of 
infections antibiotics, antiviral and antifungal agents may be advised. Individuals may also 
choose to seek medical care for conditions that might not prompt a physician visit in a person 
without ATP6V0A2-related CL.  
3.5 CONCLUSIONS 
In our study sample, individuals with ATP6V0A2-related CL experienced a larger variety 
of infections and higher rates of these infections when compared to their heterozygous 
unaffected relatives and individuals with ELN-related CL.   
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Although interpretation is limited by our small sample size, this finding suggests an 
increased susceptibility to infections, a feature that has not previously been reported in 
ATP6V0A2-related CL.  This finding may ultimately improve our understanding of the 
ATP6V0A2-related CL phenotype and provide important information about the natural history of 
CL.  Our results also have potential impact for medical management of this rare condition, 
including increased surveillance and medical intervention as appropriate.     
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4.0  RESEARCH SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH 
Rare diseases are an important area of focus for public health.  Individually, they are rare, 
but taken together, they affect between twenty-five and thirty million Americans (National 
Institutes of Health, n.d.).  The principle of justice requires that even though a disease is rare, 
affected individuals are equally entitled to treatment as individuals with more common 
conditions.  The principle of beneficence also requires that we do not abandon individuals who 
are suffering (Gericke, Riesberg, & Busse, 2005).  These principles make it an ethical imperative 
to develop treatments for rare conditions.   Understanding the features and natural history of a 
disease is necessary for the core public health function of assessment.  This information also 
provides a foundation for research on treatments (Field & Boat, 2010).    
Rare diseases often have relevance to more prevalent disorders (Gericke et al., 2005).  
CL, in particular, has features in common with pulmonary diseases such as asthma and COPD.  
Cutis laxa also has relevance for congenital heart disease and adult onset cardiovascular disease.  
ATP6V0A2-related cutis laxa, as a congenital disorder of glycosylation, is part of a larger family 
of disorders.   There are over 100 known CDGs and more are being identified all the time (Lyons 
et al., 2015).  Therefore, new knowledge about cutis laxa and the mechanisms that cause its 
features has the potential to impact a large population.         
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CL is a progeroid disorder, and as such has relevance to aging.  While CL has not yet 
been studied in this context, evidence from other progeroid conditions suggests that there is some 
similarity at a cellular level between progeria and normal aging (Dreesen & Stewart, 2011).   
Needless to say, aging affects one hundred percent of the population.  As the average age of US 
population continues to rise, this issue will continue to increase in relevance (He, Goodkind, & 
Kowal, 2016).   The aged immune system is less robust than the immune system of an adult 
(Maue et al., 2009), and identification of the mechanism causing immune deficiency in 
ATP6V0A2-related CL may lead to greater understanding of immune function in old age. 
CL is a multisystem disease, and our findings here suggest that the immune system may 
also be impacted in at least one form of CL.  This serves as an example of the need for a 
multidisciplinary approach in the management of rare diseases.   The approach used to manage 
care for CL applies to other connective tissue conditions, such as Marfan syndrome (von 
Kodolitsch et al., 2016) and Loeys-Dietz syndrome (MacCarrick et al., 2014).  In addition, our 
immune questionnaire provides an example of a non-invasive clinical instrument that has the 
potential to guide genetic testing.  It could be used for patients with a complex presentation and a 
differential diagnosis that includes a CDG or a CL subtype. Standardized assessment and 
management approaches support the public health function of policy development, and 
evaluation tools such as the infection history questionnaire support the public health function of 
assessment.   
Our CL clinic also contributes to the public health functions of assessment and policy 
development by generating data about genotype-phenotype relationships that can lead to 
improvements in diagnosis and management guidelines.  Characterization of the features of CL 
allows for both improved assessment and improved management. This study demonstrated the 
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potential of the newly developed immune history questionnaire to characterize immune 
involvement in CL and to identify individuals who may benefit from increased interventions to 
prevent or limit infections.  Another recent study that emerged from the CL clinic demonstrated 
that a non-invasive skin elasticity measurement could differentiate individuals with CL from 
individuals without CL (Kozel et al., 2014).  Since the diagnosis of CL is subjective unless a 
genetic cause can be identified, this technique has the potential to dramatically improve our 
ability to diagnose CL. 
CL and other rare conditions have special relevance in the practice of genetic counseling.  
Among families and individuals affected by rare diseases, the search for a diagnosis is 
commonly referred to as “the diagnostic odyssey”.  This term conveys the fatigue and frustration 
expressed by parents and affected individuals during a time of uncertainty (Carmichael, Tsipis, 
Windmueller, Mandel, & Estrella, 2015).  Rare diseases are frequently misdiagnosed, prolonging 
the odyssey (Anderson, Elliott, & Zurynski, 2013; Carmichael et al., 2015).  In addition to the 
stress of uncertainty, families affected by rare diseases often have financial concerns, concerns 
about competence, and social isolation (Pelentsov, Fielder, Laws, & Esterman, 2016).  
A diagnosis is beneficial because it can provide a prognosis, promote the formation of 
coping strategies, and facilitate connections to medical and social support.  Lenhard and 
colleagues demonstrated that parents of children with a diagnosis of Down syndrome scored 
higher on measures of psycho-emotional status than parents of children with a nonspecific 
diagnosis of intellectual disability (Lenhard, Breitenbach, Ebert, Schindelhauer-Deutscher, & 
Henn, 2005).   
In the case of rare disease, the diagnosis does not always provide these sources of relief 
for individuals and their families.  There are few experienced care providers for rare conditions, 
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and social support is less likely to be available locally.  In these cases families would benefit 
from additional resources and psychosocial support (Anderson et al., 2013; Dogba et al., 2016; 
Doyle, 2015; Rosell et al., 2016; Takeuchi, Muraoka, Yamada, Nishio, & Hozumi, 2016).  
A genetic counselor is uniquely positioned to bridge this gap by researching information about 
the condition, information about clinical research and online support groups, as well as 
immediate psychosocial supports for individuals and families (Helm, 2015).  
The CL research clinic is the only one of its type in the world.  At present, it is the only 
US event at which individuals and families affected by CL can meet one another.  In addition, 
the clinicians and technicians who participate in the CL research clinic have more experience 
with CL than any other group in the world.  The CL clinic is more than a data collection event.  
It is also an opportunity for a population affected by rare disease to come together to enhance 
their own health and psychosocial well-being while adding to scientific knowledge about the 
condition.   
It is important to have a complete picture of the range of possible manifestations in CL, 
so that parents and patients are empowered with as much information as possible (Aymé, Kole, 
& Groft, 2008).  This study provides information about previously unknown immunological 
features in ATP6V0A2-related CL, and thus has the potential to improve the experiences of 
families and individuals coping with a diagnosis, and to improve medical management for 
individuals affected by this condition.  
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APPENDIX B:  INFECTION HISTORY QUESTIONNAIRE 
 
 
Infection History Questionnaire 
 
 
We are asking all study participants to complete this questionnaire, which will help us to investigate a 
possible link between cutis laxa and immune disorders. Your responses are CONFIDENTIAL.  Clinic staff 
may contact you to obtain additional information about any suspected or diagnosed infections you have 
had.  If you have any questions about the questionnaire items, please contact Michelle Morrow by email 
(cutislax@pitt.edu) or by phone (412) 383-7369.  
 
1) Have you had (diagnosed or suspected) oral or genital herpes?  Symptoms of oral herpes 
include blisters or sores around the mouth, symptoms of genital herpes include blisters or sores 
on or around the genitals or rectum. 
 
_____Not sure (go to question #2) 
_____No (go to question # 2) 
 _____Yes  (if yes, clinic staff will contact you with additional questions) 
 
FOR CLINIC STAFF:  please answer questions below 
A) Has the infection been proven?   
   _____No 
   _____Yes  
B) Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
  If yes, which?  ______________________________________________ 
C) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
D) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
E) Did the infection require treatment? 
_____No 
_____Yes 
 If yes, what treatment?_______________________________________ 
 
 
2) Have you had (diagnosed or suspected) cytomegalovirus (CMV),  Epstein Barr virus (EBV), or 
mononucleosis?  These viruses may cause no symptoms, but they can also produce symptoms 
similar to mononucleosis, including fatigue, malaise, sore throat, fever, swollen glands, swollen 
tonsils, headache, skin rash, or swollen spleen. 
 
_____Not sure (go to question #3) 
_____No (go to question #3) 
 _____ Yes  (if yes, clinic staff will contact you with additional questions) 
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FOR CLINIC STAFF:  (please answer questions below) 
A) Has the infection been proven?   
   _____No 
   _____Yes  
B) Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
  If yes, which?  ______________________________________________ 
C) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
D) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
E) Did the infection require treatment? 
_____No 
_____Yes 
 If yes, what treatment?_______________________________________ 
 
3) Have you had (diagnosed or suspected) chicken pox (varicella virus, varicella zoster virus) or 
complications from the chicken pox vaccine?  Symptoms of chicken pox include an itchy rash 
with raised bumps and blisters, as well as fever, headache, and malaise.   
 
_____Not sure (go to question #4) 
_____No (go to question #4) 
 _____ Yes  (if yes, clinic staff will contact you with additional questions) 
 
FOR CLINIC STAFF:  please answer questions below 
A) Has the infection been proven?   
   _____No 
   _____Yes  
B) Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
  If yes, which?  ______________________________________________ 
C) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
D) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
E) Did the infection require treatment? 
_____No 
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_____Yes 
 If yes, what treatment?_______________________________________ 
F) If you experienced complications from the chicken pox vaccine, please describe 
below. 
 
4) Have you had a (diagnosed or suspected) infection with human papilloma virus (HPV)?  HPV 
causes warts on the hands, feet, face, neck, or genitals.   
 
_____Not sure (go to question #5) 
_____No (go to question #5) 
 _____ Yes  (if yes, clinic staff will contact you with additional questions) 
 
FOR CLINIC STAFF:  please answer questions below 
A)    Has the infection been proven?   
   _____No 
   _____Yes  
B)  Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
  If yes, which?  ______________________________________________ 
C) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
D) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
E) Did the infection require treatment? 
_____No 
_____Yes 
 If yes, what treatment?_______________________________________ 
 
5) Have you had a (diagnosed or suspected) infection with roseola, human herpes virus (HHV) or 
other DNA virus not referred to previously?  Symptoms of roseola can include a sudden high 
fever followed by a rash that starts on the trunk and spreads to the face and limbs.   
 
_____Not sure (go to next question) 
_____No (go to next question) 
 _____ Yes  (if yes, clinic staff will contact you with additional questions) 
 
FOR CLINIC STAFF:  please answer questions below 
A)    Has the infection been proven?   
   _____No 
   _____Yes  
B)  Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
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  If yes, which?  ______________________________________________ 
C) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
D) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
E) Did the infection require treatment? 
_____No 
_____Yes 
 If yes, what treatment?_______________________________________ 
 
6) Have you had multiple cases or severe cases of influenza, the common cold, stomach flu, or 
other RNA viral infections?   
 
_____Not sure (go to question #7) 
_____No (go to question #7) 
 _____ Yes  (if yes, clinic staff will contact you with additional questions) 
 
FOR CLINIC STAFF:  please answer questions below 
A) How many times have these illnesses occurred?___________________________ 
B) How many times have these illnesses occurred in the past year?______________ 
C) Has the infection been proven?   
   _____No 
   _____Yes  
F) Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
  If yes, which?  ______________________________________________ 
G) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
H) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
I) Did the infection require specific treatment? 
_____No 
_____Yes 
 If yes, what treatment?_______________________________________ 
 
7) Have you had adverse reactions to a flu vaccine? 
 
_____Not sure (go to question #8) 
_____No (go to question #8) 
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_____Yes (please answer the following question) 
A)  was the vaccine an injection or a nasal spray?___________________________ 
 
8) Have you had a documented or suspected infection with mycobacteria, listeria, or atypical 
intracellular bacteria? 
 
_____Not sure (go to question #9) 
_____No (go to question #9) 
_____Yes  (if yes, clinic staff will contact you with additional questions) 
 
FOR CLINIC STAFF:  please answer questions below 
A) Has the infection been proven?   
   _____No 
   _____Yes  
B) Was the infection proven by culture, PCR or fluorescent assay? 
 _____No 
 _____Yes 
  If yes, which?  ______________________________________________ 
C) Has the infection resulted in hospitalization? 
_____No 
_____Yes 
 If yes, how many times?______________________________________ 
D) Was the infection associated with any complications? 
_____No 
_____Yes 
 If yes, what?________________________________________________ 
E) Did the infection require treatment? 
_____No 
_____Yes 
 If yes, what treatment?_______________________________________ 
 
9) Have you had any of the following bacterial infections?  If yes, how many times? 
A) Strep throat  
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
B) Urinary tract infections (UTI 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
C) Conjunctivitis (pink eye) 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
D) Otitis media (ear infection) 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
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E) Pneumonia 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
F) Staph infection of the skin 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
G) Bronchitis or chronic cough 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
H) Bacterial vaginal infections 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
 
10) Have you had any of the following fungal infections?  If yes, how many times?   
A) Ringworm, athlete’s foot, or jock itch 
_____No 
_____Yes 
If yes, how many times?______________________________________ 
B) Yeast infections (oral thrush, vaginal yeast infection, yeast infection of the skin) 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
C) Toenail or fingernail infections 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
D) Other (list)________________________________________________________ 
_____No 
_____Yes 
If yes, how many times?_______________________________________ 
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CUTIS LAXA 
Patient/Physician questionnaire 
Date of Exam: __________________________ 
Physician Name: __________________________ Physician Specialty: _____________________ 
(Please complete contact info on last page of questionnaire for both the participant and the physician.) 
 
RACE: 
American Indian or Alaskan   [ ] 
Asian      [ ] 
Black or African American   [ ] 
Native Hawaiian or Other Pacific Islander: [ ] 
Other race (please specify): ____________________________________________ 
Two or More Races (please specify): ____________________________________ 
White:      [ ] 
 
ETHNICITY: 
Hispanic or Latino    [ ] 
Other ethnicity (please specify): _________________________________________ 
 
Definitions: 
American Indian or Alaska Native: A person having origins in any of the original peoples of North, Central, or 
South America, and who maintains tribal affiliation or community attachment.  
Asian: A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian 
subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine 
Islands, Thailand, and Vietnam.  
Black or African American: A person having origins in any of the black racial groups of Africa. Terms such as 
“Haitian” or “Negro” can be used in addition to “Black or African American.” 
Native Hawaiian or Other Pacific Islander: A person having origins in any of the original peoples of Hawaii, 
Guam, Samoa, or other Pacific Islands.  
White: A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.  
Hispanic or Latino: A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish 
culture or origin, regardless of race. The term, “Spanish origin,” can be used in addition to “Hispanic or Latino”. 
 
 
 
 
For Study Use Only: 
Family ID: ________________________ 
Participant ID: _____________________ 
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PAST MEDICAL HISTORY 
 
Birth Data: 
Date of birth (mo/day/year):   ___/___/_____  Male:  [ ] Female:  [ ] 
Gestational age at birth: ________ weeks    
Birth weight: _________ Length: ___________  Head circumference: __________  
Amniotic fluid: Normal:  [ ]  Oligohydramnios:  [ ]  Polyhydramnios:  [ ]  
Fetal movements: Normal:  [ ]  Reduced:  [ ]   Increased:  [ ] 
Fetal ultrasound: Normal:  [ ]  Abnormal:  [ ] (see table) Not Performed:  [ ] 
 
Ultrasound Abnormalities: Gestational Age: 
  
  
  
 
Death Data: 
If deceased, date of death (mo/day/year): ____/____/____ 
Cause of death:                                                                                
             
             
                         
______________________________________________________________________________ 
 
Previous Surgical History: 
 
 
 
History of abdominal vascular surgery: Yes  [ ]       No  [ ]       ?  [ ] 
 
  
History of any facial surgeries:  Yes  [ ]       No  [ ]       ?  [ ] 
If yes, type(s) of surgeries: 
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Cosmetic surgeries: 
Face lift: Yes  [ ]  No  [ ]   Don’t Know  [ ] Date(s):___________________________    
Other: ______________________________________   Date(s):___________________________ 
           ______________________________________   Date(s):___________________________ 
 
Previous Hospitalizations: 
 
 
 
 
History of any trauma that affected the facial structure:  Yes  [ ]       No  [ ]       Don’t Know  [ ] 
If yes, document here: 
 
 
 
 
Medications: 
 
 
 
 
Allergies: Yes  [ ]       No  [ ]       Don’t Know  [ ] 
Allergens: 
 
 
 
 
Skin affected by allergies: Yes  [ ]       No  [ ]       Don’t Know  [ ] 
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3 GENERATION PEDIGREE 
Patient:_________________________________________    Paternal Ethnicity:_________________________________ 
Historian:_______________________________________    Maternal Ethnicity:________________________________ 
Completed By:________________ Date:______________    Consanguinity:____________________________________ 
Updated By:__________________ Date:______________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family Review of Systems (Please note findings on pedigree): 
LD/DD/MR Yes No Gastrointestinal Problems Yes No Diverticulae Yes No 
Respiratory Problems Yes No Genitourinary Problems Yes No Hernias Yes No 
Cardiovascular Problems Yes No Skeletal Problems Yes No Growth Delay Yes No 
Skin: At least 2-3 of the following  
(i) Loose, lax; (ii) Redundant; (iii) Inelastic; (iv) Premature aging of the skin; (v) Skin wrinkling 
Yes No 
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CLINICAL DESCRIPTION 
Age at examination: _____________________ 
Age when symptoms began: _______________ 
 
SKIN: 
Lax:    Yes  [ ]       No  [ ]       ?  [ ] 
Redundant:   Yes  [ ]       No  [ ]       ?  [ ] 
Inelastic:   Yes  [ ]       No  [ ]       ?  [ ] 
Loose facial skin:  Yes  [ ]       No  [ ]       ?  [ ] 
Premature aging of skin: Yes  [ ]       No  [ ]       ?  [ ] 
Skin wrinkling:  Yes  [ ]       No  [ ]       ?  [ ] 
Affected skin:   Generalized  [ ] Localized  [ ] 
If localized:     Symmetric  [ ]  Asymmetric  [ ]      Flexural  [ ]      Focal [ ] 
Transparent skin:  Yes  [ ]       No  [ ]       ?  [ ] 
Inflammatory skin disease: Yes  [ ]       No  [ ]       ?  [ ] 
Alopecia:   Yes  [ ]       No  [ ]       ?  [ ] Location: _____________________ 
Other skin findings: 
 
CRANIOFACIAL: 
Facial drooping:  Yes  [ ]       No  [ ]       ?  [ ] 
Wizened appearance:  Yes  [ ]       No  [ ]       ?  [ ] 
Large fontanels:  Yes  [ ]       No  [ ]       ?  [ ] 
Delayed closure of fontanels: Yes  [ ]       No  [ ]       ?  [ ] 
Oxycephaly:   Yes  [ ]       No  [ ]       ?  [ ] 
Macrocephaly:  Yes  [ ]       No  [ ]       ?  [ ]  OFC: _________________ 
Microcephaly:   Yes  [ ]       No  [ ]       ?  [ ]  OFC %ile: _____________ 
Frontal bossing:  Yes  [ ]       No  [ ]       ?  [ ] 
Reversed-V eyebrows: Yes  [ ]       No  [ ]       ?  [ ] 
Downslanting palpebral fissures:    Yes  [ ]       No  [ ]       ?  [ ] 
Hooked nose:   Yes  [ ]       No  [ ]       ?  [ ] 
Long philtrum:  Yes  [ ]       No  [ ]       ?  [ ]  Length: ___________ (cm) 
Retrognathia/Micrognathia:  Yes  [ ]       No  [ ]       ?  [ ]  (If Yes, circle which type) 
Occipital horns:  Yes  [ ]       No  [ ]       ?  [ ] 
Other craniofacial findings: 
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ORAL: 
Vocal cord laxity: Yes  [ ]       No  [ ]       ?  [ ] 
Hoarse voice:  Yes  [ ]       No  [ ]       ?  [ ] 
Dental caries:  Yes  [ ]       No  [ ]       ?  [ ]  Details: _______________________ 
Cleft palate   Yes  [ ]       No  [ ]       ?  [ ]  Details/type: ___________________ 
Bifid uvula   Yes  [ ]       No  [ ]       ?  [ ] 
Other oral findings: 
 
EYES/EARS: 
Retinovascular tortuosity: Yes  [ ]       No  [ ]       ?  [ ] 
Corneal opacities:  Yes  [ ]       No  [ ]       ?  [ ] 
Corneal arcus:   Yes  [ ]       No  [ ]       ?  [ ] 
Cataract:   Yes  [ ]       No  [ ]       ?  [ ] 
Myopia:   Yes  [ ]       No  [ ]       ?  [ ] 
Blindness:   Yes  [ ]       No  [ ]       ?  [ ] 
Hearing Loss:    Yes  [ ]       No  [ ]       ?  [ ] dB loss (left):__________________ 
Deafness:    Yes  [ ]       No  [ ]       ?  [ ]  dB loss (right):_________________ 
Other eye findings: 
 
NEUROBEHAVIORAL: 
Deep tendon reflexes:  Present [ ]  Absent [ ]  Not Checked [ ] 
Hypotonia:   Yes  [ ]       No  [ ]       ?  [ ] 
Cong. bilateral athetosis: Yes  [ ]       No  [ ]       ?  [ ] 
Seizures:   Yes  [ ]       No  [ ]       ?  [ ] Frequency: ____________________ 
Autism:   Yes  [ ]       No  [ ]       ?  [ ] Details: _______________________ 
Mental retardation:  Yes  [ ]       No  [ ]       ?  [ ]   IQ Test:_________ Score:_________ 
Education history: 
Social history: 
Other neurobehavioral findings: 
 
RESPIRATORY: 
Bronchiectasis:  Yes  [ ]       No  [ ]       ?  [ ] 
Hypoplastic lungs (newborn): Yes  [ ]       No  [ ]       ?  [ ] 
Emphysema:   Yes  [ ]       No  [ ]       ?  [ ] 
Tachypnea:   Yes  [ ]       No  [ ]       ?  [ ] 
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Pneumonia:   Yes  [ ]       No  [ ]       ?  [ ] Frequency: ____________________ 
Asthma:   Yes  [ ]       No  [ ]       ?  [ ] Type: ________________________ 
Chest CT findings and date: ___________________________________________ 
Pulmonary function test (PFT) findings and date:  ___________________________ 
Current smoker:  Yes  [ ]       No  [ ]        
Cigarette packs per day: ___________________________ 
Years smoked:  ___________________________ 
Other respiratory findings: 
 
CARDIOVASCULAR: 
Cor pulmonale:     Yes  [ ]       No  [ ]       ?  [ ] 
Right ventricular hypertrophy:  Yes  [ ]       No  [ ]       ?  [ ] 
Infundibular stenosis:     Yes  [ ]       No  [ ]       ?  [ ] 
Pulmonary valve stenosis:    Yes  [ ]       No  [ ]       ?  [ ] 
Pulmonary artery stenosis:    Yes  [ ]       No  [ ]       ?  [ ] 
Peripheral pulmonary stenosis: Yes  [ ]       No  [ ]       ?  [ ] 
Supravalvular aortic stenosis:  Yes  [ ]       No  [ ]       ?  [ ] 
Valvular aortic stenosis:  Yes  [ ]       No  [ ]       ?  [ ] 
Heart Murmur:   Yes  [ ]       No  [ ]       ?  [ ] 
Murmur (6 scale):________________ 
Aortic dilatation:  Yes  [ ]       No  [ ]       ?  [ ] 
 Level:____________  Diameter:______________ 
Arterial tortuosity:  Yes  [ ]       No  [ ]       ?  [ ] 
 Which arteries:____________________________ 
Arterial aneurysms:  Yes  [ ]       No  [ ]       ?  [ ] 
 Which arteries:____________________________ 
Raynaud’s phenomenon: Yes  [ ]       No  [ ]       ?  [ ] 
Venous varicosity:  Yes  [ ]       No  [ ]       ?  [ ] 
Echocardiogram:   Yes  [ ]       No  [ ]       ?  [ ] 
(Echo) findings and date:__________________________________ 
Edema?   Yes  [ ]       No  [ ]       ?  [ ] Details: _______________________ 
Other cardiovascular findings: 
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GASTROINTESTINAL: 
Diverticulae: Esophageal: Yes  [ ]       No  [ ]       ?  [ ] 
  Intestinal: Yes  [ ]       No  [ ]       ?  [ ] 
  Rectal:  Yes  [ ]       No  [ ]       ?  [ ] 
  Other:_____________________________ 
Other gastrointestinal findings: 
 
GENITOURINARY: 
Bladder diverticulae:  Yes  [ ]       No  [ ]       ?  [ ] 
Obstructive uropathy:  Yes  [ ]       No  [ ]       ?  [ ] 
Bladder neck obstruction: Yes  [ ]       No  [ ]       ?  [ ] 
Other genitourinary findings: 
 
MUSCULOSKELETAL: 
Hernias: Inguinal:  Yes  [ ]       No  [ ]       ?  [ ] 
  Diaphragmatic: Yes  [ ]       No  [ ]       ?  [ ] 
Hiatal:   Yes  [ ]       No  [ ]       ?  [ ] 
Umbilical:  Yes  [ ]       No  [ ]       ?  [ ] 
Genital/Bladder/Rectal Prolapse Yes  [ ]       No  [ ]       ?  [ ] Details: _________________ 
Hip dislocation:   Yes  [ ]       No  [ ]       ?  [ ] 
Thumbs and/or toes dislocated: Yes  [ ]       No  [ ]       ?  [ ] 
Other dislocations/subluxations:   Yes  [ ]       No  [ ]       ?  [ ] Details: _________________ 
_____________________________________________________________________________________________ 
Joint pain:    Yes  [ ]       No  [ ]       ?  [ ] 
Joint laxity:   Yes  [ ]       No  [ ]       ?  [ ] 
Fractures:   Yes  [ ]       No  [ ]       ?  [ ] #/Site(s): ______________________ 
Osteopenia/Osteoporosis:  Yes  [ ]       No  [ ]       ?  [ ] Hip?  [ ]       Spine?  [ ]       Total?  [ ] 
Pectus carinatum:  Yes  [ ]       No  [ ]       ?  [ ] 
Pectus excavatum:  Yes  [ ]       No  [ ]       ?  [ ] 
Scoliosis:   Yes  [ ]       No  [ ]       ?  [ ] Degree: _______________________ 
Flat feet:   Yes  [ ]       No  [ ]       ?  [ ] 
Short broad clavicles:  Yes  [ ]       No  [ ]       ?  [ ] 
Fused carpal bones:  Yes  [ ]       No  [ ]       ?  [ ] 
Other musculoskeletal findings: 
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GROWTH: 
Growth deficiency/delay: 
 Prenatal: Yes  [ ]       No  [ ]       ?  [ ] 
 Postnatal Yes  [ ]       No  [ ]       ?  [ ] 
 Dwarfism Yes  [ ]       No  [ ]       ?  [ ] 
Physical data: 
Age Weight Height Head Circumference 
    
    
 
OTHER ABNORMALITIES NOT LISTED ABOVE: 
             
             
              
 
LABORATORY: 
Abnormal elastic fibers: 
  Histology: Yes  [ ]       No  [ ]       ?  [ ] 
  EM:  Yes  [ ]       No  [ ]       ?  [ ] 
Glycosylation Testing: Yes  [ ]       No  [ ]       ?  [ ] Result: _______________________ 
Genetic testing:   Yes  [ ]       No  [ ]       ?  [ ] Details/Result:    ________________ 
______________________________________________________________________________ 
Serum ceruloplasmin:_____________________________ 
Serum copper:___________________________________ 
 
ADDITIONAL INFORMATION: 
Clinical photographs available: Yes  [ ]       No  [ ] 
DNA available:   Yes  [ ]       No  [ ] 
Cultured cells available:  Yes  [ ]       No  [ ] 
Pathology slides available:  Yes  [ ]       No  [ ] 
Frozen tissue available:  Yes  [ ]       No  [ ] 
Imaging Studies:    Yes  [ ]       No  [ ] Details: _______________________ 
Patient available for re-examination: Yes  [ ]       No  [ ] 
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CUTIS LAXA 
Contact Information 
 
PARTICIPANT:  
 
Family ID:  __________________________ (to be filled in by study coordinator) 
Participant ID: ________________________ (to be filled in by study coordinator) 
 
Participant’s Name:_____________________________________________________________ 
Parent’s or Guardian’s Name (if participant is minor):__________________________________ 
Address:______________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
Home Phone: _____________________________ Cell Phone: ___________________________ 
Fax:_____________________________________ 
EMAIL:___________________________________________________ 
 
REFERRING PHYSICIAN: 
 
Physician’s Name: _____________________________________________________________ 
Physician Address: _____________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
Phone: __________________________________ 
Fax:_____________________________________ 
EMAIL:___________________________________________________ 
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APPENDIX D: CUTIS LAXA STUDY SCREENING SCRIPT 
 
Participant ID _______________ 
Family ID _______________ 
Phone Screening Script for 
Genetics of Extracellular Matrix in Health and Disease 
 
Telephone Screen Results: 
 
___ Agreed and Eligible  ___ Refused   ___ Not eligible   
 
___________________________________ 
Printed Name of Participant 
 
___________________________________   ______________________ 
Printed Name of Person Screening    Date and Time of Screen 
 
Notes: ________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
Script ---------------------------------------------------------------------------------------------------- 
 
“Hello.  My name is ___________________ and I am researcher with the University of 
Pittsburgh Department of Human Genetics.  May I please speak with ____________?” 
 
{If the potential participant is not available}  
“OK, thank you.  I’ll call back at another time.  Is there a better day or time to reach them?” 
  
{If yes} Document here: ____________________________________________ 
  “Great.  I’ll call back then.  Thank you.  Goodbye.” 
 {If no} “OK.  Thank you.  Goodbye.” 
 
{If the potential participant is available on the phone} 
“Hello.  Again, my name is _______________ and I am a researcher at the University of 
Pittsburgh.  I work on studies of cutis laxa. You expressed interest in participating in our study 
about looking at the genetic causes of cutis laxa.   
 
May I talk to you today about our study that is looking at cutis laxa causing genes?” 
 
{If no}:  “OK.  Thank you very much for your time.  Have a nice day.” 
 
{If yes}:   “OK.  In this study, we are looking at several genes that have been shown to cause 
cutis laxa. We are interested in using clinical and laboratory information to find disease-
causing changes in known genes and to identify new cutis laxa genes. We also will study the 
effects of the gene changes and how they cause cutis laxa.   
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 2 
Are you interested in hearing more about the study?” 
 
{If no}:  “OK.  Thank you very much for your time.  Have a nice day.” 
 
{If yes}:   “Great! But before enrolling people in the study, we need to make sure that you are 
eligible.  What I would like to do now is ask you a series of questions about your or your family 
member’s health and medical history, specifically pertaining to the skin.  All information that I 
receive from you today by phone will be strictly confidential and stored under lock and key in 
our files to be reviewed only by our research staff.  The purpose of these questions is to 
determine if you are eligible for our study, and if you are found not to be eligible the 
information will be destroyed.  Your participation in this interview is voluntary; you do not have 
to answer these questions, and can choose to stop answering these questions at any time. 
 
Do I have your permission to ask you these questions now?” 
 
No ___ Yes ___ 
 
___________________________________   ______________________ 
Printed Name of Person Obtaining Consent   Role in Research Study 
 
___________________________________   ______________________ 
Signature of Person Obtaining Consent   Date and Time of Consent 
 
____ All questions were answered to the participant’s satisfaction:   
 
 Document here: 
 __________________________________________________________________ 
 __________________________________________________________________ 
__________________________________________________________________ 
__________________________________________________________________ 
 
 ____  Participant had no questions. 
 
 
{If no}: “OK.  Thank you very much for your time.  Have a nice day.” 
 
{If yes}: “Great!  If at any time you have questions, please stop me and ask your question. 
 
1) “Have you or a family member ever been diagnosed with cutis laxa, has cutis laxa been 
suspected in you or a family member, or have you or a family member had genetic testing that 
identified a change in a cutis laxa related gene?” 
 
___ (A) Yes, cutis laxa has been diagnosed in participant 
  
“Who diagnosed you with cutis laxa?”___________________ 
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 3 
“How old were you when diagnosed?”___________________ 
 
___ (B) Yes, cutis laxa has been suspected in participant 
 
“Who suspected that you have cutis laxa?”___________________ 
 
“How old were you when cutis laxa was suspected?”___________________ 
 
___ (C) Yes, cutis has been diagnosed in a participant’s family member 
  
“How are you related to your family member who has cutis laxa?”_____________________ 
  
___ (D) Yes, cutis laxa has been suspected in family member 
  
“How are you related to your family member who is suspected to have cutis laxa?” 
________________________________ 
 
___(E) Yes, genetic testing has identified a variant (change) in a cutis laxa related gene in 
participant 
 
“What gene contained the change?”_______________________ 
 
“What type of genetic testing found the change?”_____________________________ 
 
___(F) Yes, genetic testing has identified a variant (change) in a cutis laxa related gene in 
participant’s family member 
 
“What gene contained the change?”_______________________ 
 
“What type of genetic testing found the change?”_____________________________ 
 
“How are you related to your family member with the cutis laxa related genetic 
change?”__________________________________________________   
 
___ (G) No. Continue with question #2. 
 
 
2) “I am now going to ask you a few questions about [your/your family member’s] skin: 
 
[Do you/ does your family] have: 
  
 (A) Loose, lax skin   ___ Yes ___ No 
 
 (B) Skin in redundant folds  ___ Yes ___ No 
 
 (C) Inelastic (doughy) skin  ___ Yes ___ No 
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 (D) Premature aging of the skin ___ Yes ___ No 
 
 (E) Excessive premature wrinkling ___ Yes ___ No 
 
Additional notes about features: 
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________ 
___ Participant or participant’s first degree family member has 3 or more of the above 
features.  {If yes}: Subject is eligible to participate.  Skip question #3 below. 
 
___ Participant or participant’s family member does not have 3 or more of the above features.  {If 
no}: Continue with additional screening question #3 below to determine eligibility. 
 
NOTE: A check mark next to A, B, C, D, E, or F in Question 1 counts as one feature. 
 
3) “I am now going to ask you a few additional questions about [your/your family member’s] 
health: 
 
[Do you/ does your family] have: 
  
 (A) Arterial or venous tortuosity?  ___ Yes ___ No 
 
 (B) Aortic dilation or aneurysm?  ___ Yes ___ No 
 
 (C) Vascular or valve stenosis?  ___ Yes ___ No 
  
 (D) Emphysema or chronic lung disease? ___ Yes ___ No 
 
 (E) Hernia or diverticulae?   ___ Yes ___ No 
 
 (F) Spinal disease such as herniated  ___ Yes ___ No 
 disc or dural ectasia? 
 
Additional notes about features: 
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________ 
 
___ Participant or participant’s first degree family member has 1 of the above features and 
possible cutis laxa.  If yes, subject is eligible to participate. 
 
___ Participant or participant’s family member does not have any of the above features.  If this 
option is checked, stop screening – subject is ineligible.  Tell the subject.  “Ok.  Well I am 
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 (D) Premature aging of the skin ___ Yes ___ No 
 
 (E) Excessive premature wrinkling ___ Yes ___ No 
 
Additional notes about features: 
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________ 
___ Participant or participant’s first degree family member has 3 or more of the above 
features.  {If yes}: Subject is eligible to participate.  Skip question #3 below. 
 
___ Participant or participant’s family member does not have 3 or more of the above features.  {If 
no}: Continue with additional screening question #3 below to determine eligibility. 
 
NOTE: A check mark next to A, B, C, D, E, or F in Question 1 counts as one feature. 
 
3) “I am now going to ask you a few additional questions about [your/your family member’s] 
health: 
 
[Do you/ does your family] have: 
  
 (A) Arterial or venous tortuosity?  ___ Yes ___ No 
 
 (B) Aortic dilation or aneurysm?  ___ Yes ___ No 
 
 (C) Vascular or valve stenosis?  ___ Yes ___ No 
  
 (D) Emphysema or chronic lung disease? ___ Yes ___ No 
 
 (E) Hernia or diverticulae?   ___ Yes ___ No 
 
 (F) Spinal disease such as herniated  ___ Yes ___ No 
 disc or dural ectasia? 
 
Additional notes about features: 
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________ 
 
___ Participant or participant’s first degree family member has 1 of the above features and 
possible cutis laxa.  If yes, subject is eligible to participate. 
 
___ Participant or participant’s family member does not have any of the above features.  If this 
option is checked, stop screening – subject is ineligible.  Tell the subject.  “Ok.  Well I am 
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sorry to tell you, but you are not eligible for our study.  We do appreciate your time today on 
the phone.  Thank you. Goodbye.” 
 
 
For subjects who have passed the screening questions: “Based on the questions I have asked, 
you are eligible for the study.  
 
“The next step is to provide you with all the relevant information you will need to make an 
informed decision about participating in the study. Do you have the packet you received [in the 
mail / from your physician] called ‘Consent to Act as a Participant in a Research Study’?” 
 
{If no}: “OK.  What we can do is send you another packet, and you can contact us once you have 
received the packet.” 
 
{If yes}: “This will take about 15 minutes to go through, do you have enough time right now?” 
 
{If yes}: Move onto “Informed Consent Script for Genetics of Extracellular Matrix in Health 
and Disease” 
 
{If no}: “When will be a better time to contact you to go through this packet?” 
 
Contact date and time: ____________________________________  
 
“Before going, I would like to ensure that we have your correct contact information: 
Name:   ____________________________ 
Contact Address: ____________________________ 
   ____________________________ 
   ____________________________ 
   ____________________________ 
Contact Telephone: ____________________________ 
Best time to call: ____________________________ 
Contact Email: ____________________________ 
 
Thank you very much for your time. Have a nice day.” 
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